https://trial.medpath.com/news/tempus-ai-receives-fda-510-k-clearance-for-rna-based-cancer-diagnostic-device 2025-09-22T17:12:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-ai-receives-fda-510-k-clearance-for-rna-based-cancer-diagnostic-device 2025-09-22T17:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/techsomed-expands-ai-powered-biotraceio360-platform-to-kidney-ablation-following-fda-510-k-clearance 2025-09-22T17:12:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/techsomed-expands-ai-powered-biotraceio360-platform-to-kidney-ablation-following-fda-510-k-clearance 2025-09-22T17:12:24+00:00 hourly 0.9 https://trial.medpath.com/news/usc-scientists-create-most-advanced-lab-grown-kidney-structures-with-real-function-for-disease-modeling 2025-09-22T17:12:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usc-scientists-create-most-advanced-lab-grown-kidney-structures-with-real-function-for-disease-modeling 2025-09-22T17:12:22+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-and-bristol-myers-squibb-report-promising-phase-2-results-for-pumitamig-in-triple-negative-breast-cancer 2025-09-22T17:11:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biontech-and-bristol-myers-squibb-report-promising-phase-2-results-for-pumitamig-in-triple-negative-breast-cancer 2025-09-22T17:11:48+00:00 hourly 0.9 https://trial.medpath.com/news/sharp-services-announces-100-million-global-investment-to-expand-injectable-drug-manufacturing-capacity 2025-09-22T13:16:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sharp-services-announces-100-million-global-investment-to-expand-injectable-drug-manufacturing-capacity 2025-09-22T13:16:34+00:00 hourly 0.9 https://trial.medpath.com/news/nuclide-therapeutics-secures-ps5m-to-advance-aldh1a1-targeted-radiotheranostics-for-therapy-resistant-cancers 2025-09-22T13:15:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuclide-therapeutics-secures-ps5m-to-advance-aldh1a1-targeted-radiotheranostics-for-therapy-resistant-cancers 2025-09-22T13:15:12+00:00 hourly 0.9 https://trial.medpath.com/news/hetero-healthcare-and-enzene-launch-perzea-india-s-most-affordable-pertuzumab-biosimilar-for-her2-positive-breast-cancer 2025-09-22T13:14:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hetero-healthcare-and-enzene-launch-perzea-india-s-most-affordable-pertuzumab-biosimilar-for-her2-positive-breast-cancer 2025-09-22T13:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/european-medicines-agency-recommends-approval-of-alvotech-s-gobivaz-biosimilar-to-johnson-johnson-s-simponi 2025-09-22T13:13:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-medicines-agency-recommends-approval-of-alvotech-s-gobivaz-biosimilar-to-johnson-johnson-s-simponi 2025-09-22T13:13:53+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-secures-multiple-fda-approvals-boosting-pharmaceutical-portfolio-and-market-outlook 2025-09-22T13:12:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-secures-multiple-fda-approvals-boosting-pharmaceutical-portfolio-and-market-outlook 2025-09-22T13:12:36+00:00 hourly 0.9 https://trial.medpath.com/news/tolvaptan-shows-promise-as-universal-pharmacological-chaperone-for-rare-disease-treatment 2025-09-22T13:12:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tolvaptan-shows-promise-as-universal-pharmacological-chaperone-for-rare-disease-treatment 2025-09-22T13:12:30+00:00 hourly 0.9 https://trial.medpath.com/news/n4-pharma-s-nuvec-delivery-system-achieves-targeted-rna-delivery-to-lung-cancer-cells 2025-09-22T13:12:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/n4-pharma-s-nuvec-delivery-system-achieves-targeted-rna-delivery-to-lung-cancer-cells 2025-09-22T13:12:07+00:00 hourly 0.9 https://trial.medpath.com/news/ensoma-secures-53-million-to-advance-first-in-class-gene-therapy-for-x-linked-chronic-granulomatous-disease 2025-09-22T13:10:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensoma-secures-53-million-to-advance-first-in-class-gene-therapy-for-x-linked-chronic-granulomatous-disease 2025-09-22T13:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/debra-research-and-nonsense-therapeutics-form-readon-therapeutics-to-advance-epidermolysis-bullosa-treatments 2025-09-22T13:10:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/debra-research-and-nonsense-therapeutics-form-readon-therapeutics-to-advance-epidermolysis-bullosa-treatments 2025-09-22T13:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/phase-scientific-launches-world-s-largest-urine-based-hpv-screening-study-with-17000-participants 2025-09-22T13:09:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-scientific-launches-world-s-largest-urine-based-hpv-screening-study-with-17000-participants 2025-09-22T13:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-plans-2026-uk-launch-of-breakthrough-schizophrenia-drug-cobenfy-at-22500-annual-price 2025-09-22T13:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-plans-2026-uk-launch-of-breakthrough-schizophrenia-drug-cobenfy-at-22500-annual-price 2025-09-22T13:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/c4x-discovery-selects-once-daily-oral-a4b7-inhibitor-candidate-for-inflammatory-bowel-disease-treatment 2025-09-22T09:21:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/c4x-discovery-selects-once-daily-oral-a4b7-inhibitor-candidate-for-inflammatory-bowel-disease-treatment 2025-09-22T09:21:51+00:00 hourly 0.9 https://trial.medpath.com/news/gc-green-cross-submits-phase-1-clinical-trial-application-for-covid-19-mrna-vaccine-in-south-korea 2025-09-22T09:18:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gc-green-cross-submits-phase-1-clinical-trial-application-for-covid-19-mrna-vaccine-in-south-korea 2025-09-22T09:18:59+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-pursues-7-3-billion-acquisition-of-metsera-to-enter-rapidly-expanding-anti-obesity-drug-market 2025-09-22T09:16:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-pursues-7-3-billion-acquisition-of-metsera-to-enter-rapidly-expanding-anti-obesity-drug-market 2025-09-22T09:16:50+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-tezspire-receives-eu-regulatory-recommendation-for-chronic-rhinosinusitis-with-nasal-polyps 2025-09-22T09:16:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-tezspire-receives-eu-regulatory-recommendation-for-chronic-rhinosinusitis-with-nasal-polyps 2025-09-22T09:16:28+00:00 hourly 0.9 https://trial.medpath.com/news/myricx-bio-appoints-new-ceo-as-company-advances-novel-adc-platform-toward-clinical-trials 2025-09-22T09:15:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myricx-bio-appoints-new-ceo-as-company-advances-novel-adc-platform-toward-clinical-trials 2025-09-22T09:15:40+00:00 hourly 0.9 https://trial.medpath.com/news/idorsia-s-quviviq-launches-in-china-through-simcere-partnership-expanding-global-reach-of-novel-insomnia-treatment 2025-09-22T09:14:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/idorsia-s-quviviq-launches-in-china-through-simcere-partnership-expanding-global-reach-of-novel-insomnia-treatment 2025-09-22T09:14:25+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-s-ipn10200-shows-superior-long-term-efficacy-in-phase-ii-glabellar-lines-trial 2025-09-22T09:13:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-s-ipn10200-shows-superior-long-term-efficacy-in-phase-ii-glabellar-lines-trial 2025-09-22T09:13:47+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-giredestrant-combination-meets-phase-iii-endpoints-in-advanced-breast-cancer 2025-09-22T09:13:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-giredestrant-combination-meets-phase-iii-endpoints-in-advanced-breast-cancer 2025-09-22T09:13:41+00:00 hourly 0.9 https://trial.medpath.com/news/proteomics-international-achieves-iso-15189-certification-accelerates-commercial-launch-of-precision-diagnostic-tests 2025-09-22T09:13:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proteomics-international-achieves-iso-15189-certification-accelerates-commercial-launch-of-precision-diagnostic-tests 2025-09-22T09:13:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-in-human-trial-for-lbl-047-novel-bispecific-protein-targeting-autoimmune-diseases 2025-09-22T09:12:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-first-in-human-trial-for-lbl-047-novel-bispecific-protein-targeting-autoimmune-diseases 2025-09-22T09:12:07+00:00 hourly 0.9 https://trial.medpath.com/news/crossject-receives-additional-11-3m-barda-funding-for-zepizure-needle-free-epilepsy-treatment 2025-09-22T09:12:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crossject-receives-additional-11-3m-barda-funding-for-zepizure-needle-free-epilepsy-treatment 2025-09-22T09:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-ianalumab-combination-shows-45-improvement-in-itp-disease-control-in-phase-iii-trial 2025-09-22T07:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-ianalumab-combination-shows-45-improvement-in-itp-disease-control-in-phase-iii-trial 2025-09-22T07:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/yangtze-river-pharmaceutical-unveils-phase-iii-results-for-novel-insomnia-drug-fazamorexant-at-world-sleep-congress 2025-09-22T05:17:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yangtze-river-pharmaceutical-unveils-phase-iii-results-for-novel-insomnia-drug-fazamorexant-at-world-sleep-congress 2025-09-22T05:17:48+00:00 hourly 0.9 https://trial.medpath.com/news/gemvax-seeks-fda-breakthrough-therapy-designation-for-gv1001-in-progressive-supranuclear-palsy 2025-09-22T05:17:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gemvax-seeks-fda-breakthrough-therapy-designation-for-gv1001-in-progressive-supranuclear-palsy 2025-09-22T05:17:44+00:00 hourly 0.9 https://trial.medpath.com/news/ceretas-secures-2-4-million-government-grant-to-advance-non-invasive-ultrasound-therapy-for-alzheimer-s-disease 2025-09-22T05:17:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ceretas-secures-2-4-million-government-grant-to-advance-non-invasive-ultrasound-therapy-for-alzheimer-s-disease 2025-09-22T05:17:28+00:00 hourly 0.9 https://trial.medpath.com/news/ltr-pharma-increases-stake-in-levomega-to-43-with-1m-investment-for-sustainable-omega-3-development 2025-09-22T01:10:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ltr-pharma-increases-stake-in-levomega-to-43-with-1m-investment-for-sustainable-omega-3-development 2025-09-22T01:10:02+00:00 hourly 0.9 https://trial.medpath.com/news/positive-trial-shows-tildrakizumab-delivers-comprehensive-quality-of-life-benefits-in-psoriatic-disease 2025-09-21T21:12:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/positive-trial-shows-tildrakizumab-delivers-comprehensive-quality-of-life-benefits-in-psoriatic-disease 2025-09-21T21:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-secures-fda-approval-for-altaviva-tibial-neuromodulation-device-becomes-sole-provider-of-complete-bladder-control-portfolio 2025-09-21T21:11:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-secures-fda-approval-for-altaviva-tibial-neuromodulation-device-becomes-sole-provider-of-complete-bladder-control-portfolio 2025-09-21T21:11:28+00:00 hourly 0.9 https://trial.medpath.com/news/magnesium-supplements-show-promise-for-colorectal-cancer-prevention-through-gut-microbiome-modulation 2025-09-21T17:09:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/magnesium-supplements-show-promise-for-colorectal-cancer-prevention-through-gut-microbiome-modulation 2025-09-21T17:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-helios-trial-shows-promise-for-otx-tki-in-diabetic-retinopathy-treatment 2025-09-21T17:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-helios-trial-shows-promise-for-otx-tki-in-diabetic-retinopathy-treatment 2025-09-21T17:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-infiltrating-lymphocytes-and-macrophages-drive-cancer-immunoediting-through-three-critical-phases 2025-09-21T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tumor-infiltrating-lymphocytes-and-macrophages-drive-cancer-immunoediting-through-three-critical-phases 2025-09-21T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/henagliflozin-shows-promise-as-anti-aging-therapy-in-type-2-diabetes-patients 2025-09-21T13:13:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/henagliflozin-shows-promise-as-anti-aging-therapy-in-type-2-diabetes-patients 2025-09-21T13:13:31+00:00 hourly 0.9 https://trial.medpath.com/news/our-lady-of-the-lake-cancer-institute-launches-louisiana-s-first-allogeneic-car-t-cell-therapy-clinical-trial 2025-09-21T13:12:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/our-lady-of-the-lake-cancer-institute-launches-louisiana-s-first-allogeneic-car-t-cell-therapy-clinical-trial 2025-09-21T13:12:56+00:00 hourly 0.9 https://trial.medpath.com/news/iranian-researchers-develop-ai-powered-personalized-mrna-vaccine-for-lung-cancer 2025-09-21T13:12:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iranian-researchers-develop-ai-powered-personalized-mrna-vaccine-for-lung-cancer 2025-09-21T13:12:12+00:00 hourly 0.9 https://trial.medpath.com/news/avidity-biosciences-advances-rna-therapeutics-with-clinical-trials-for-rare-diseases 2025-09-21T12:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avidity-biosciences-advances-rna-therapeutics-with-clinical-trials-for-rare-diseases 2025-09-21T12:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-show-austedo-xr-delivers-high-patient-satisfaction-and-movement-improvement-in-tardive-dyskinesia 2025-09-21T09:11:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-data-show-austedo-xr-delivers-high-patient-satisfaction-and-movement-improvement-in-tardive-dyskinesia 2025-09-21T09:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/teva-s-olanzapine-lai-shows-no-pdss-events-in-56-week-phase-3-trial-paving-way-for-first-long-acting-olanzapine-treatment 2025-09-21T05:09:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-s-olanzapine-lai-shows-no-pdss-events-in-56-week-phase-3-trial-paving-way-for-first-long-acting-olanzapine-treatment 2025-09-21T05:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/pegasus-laboratories-expands-florida-manufacturing-facility-to-meet-growing-veterinary-drug-demand 2025-09-21T01:25:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pegasus-laboratories-expands-florida-manufacturing-facility-to-meet-growing-veterinary-drug-demand 2025-09-21T01:25:09+00:00 hourly 0.9 https://trial.medpath.com/news/mmrf-presents-breakthrough-multiple-myeloma-research-at-international-conference-revealing-immune-system-changes-during-treatment 2025-09-21T01:21:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mmrf-presents-breakthrough-multiple-myeloma-research-at-international-conference-revealing-immune-system-changes-during-treatment 2025-09-21T01:21:19+00:00 hourly 0.9 https://trial.medpath.com/news/genfit-discontinues-vs-01-development-in-liver-failure-following-safety-concerns-refocuses-on-rare-disease 2025-09-20T21:13:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genfit-discontinues-vs-01-development-in-liver-failure-following-safety-concerns-refocuses-on-rare-disease 2025-09-20T21:13:30+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-receives-four-fda-observations-at-pune-biotech-facility-following-pre-approval-inspection 2025-09-20T21:11:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-receives-four-fda-observations-at-pune-biotech-facility-following-pre-approval-inspection 2025-09-20T21:11:58+00:00 hourly 0.9 https://trial.medpath.com/news/faers-analysis-reveals-lower-infection-risk-with-ide-cel-compared-to-other-bcma-targeted-therapies-in-multiple-myeloma 2025-09-20T21:10:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faers-analysis-reveals-lower-infection-risk-with-ide-cel-compared-to-other-bcma-targeted-therapies-in-multiple-myeloma 2025-09-20T21:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/elutia-s-biologic-envelope-shows-43-reduction-in-cied-reoperation-difficulty-in-heal-study 2025-09-20T21:08:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elutia-s-biologic-envelope-shows-43-reduction-in-cied-reoperation-difficulty-in-heal-study 2025-09-20T21:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/savara-receives-fda-alignment-on-molbreevi-bla-resubmission-stock-surges-15-76-following-strategic-financing 2025-09-20T17:10:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/savara-receives-fda-alignment-on-molbreevi-bla-resubmission-stock-surges-15-76-following-strategic-financing 2025-09-20T17:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/faraday-future-invests-41-million-in-qualigen-therapeutics-for-strategic-pivot-to-cryptocurrency-and-web3-business 2025-09-20T17:09:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faraday-future-invests-41-million-in-qualigen-therapeutics-for-strategic-pivot-to-cryptocurrency-and-web3-business 2025-09-20T17:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/large-australian-trial-finds-pneumococcal-vaccine-ineffective-for-cardiovascular-protection 2025-09-20T10:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-australian-trial-finds-pneumococcal-vaccine-ineffective-for-cardiovascular-protection 2025-09-20T10:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/two-major-nih-grants-totaling-7-3-million-fund-groundbreaking-adhd-medication-research 2025-09-20T09:10:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-major-nih-grants-totaling-7-3-million-fund-groundbreaking-adhd-medication-research 2025-09-20T09:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-advisory-committee-delays-vote-on-proposed-changes-to-newborn-hepatitis-b-vaccination-schedule 2025-09-20T09:10:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-advisory-committee-delays-vote-on-proposed-changes-to-newborn-hepatitis-b-vaccination-schedule 2025-09-20T09:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-reports-positive-phase-3-results-for-darzalex-faspro-combination-in-newly-diagnosed-multiple-myeloma 2025-09-20T05:10:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-reports-positive-phase-3-results-for-darzalex-faspro-combination-in-newly-diagnosed-multiple-myeloma 2025-09-20T05:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-injectable-keytruda-marking-new-era-in-cancer-treatment-convenience 2025-09-20T01:15:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-injectable-keytruda-marking-new-era-in-cancer-treatment-convenience 2025-09-20T01:15:41+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-biomed-launches-a-perfusctm-3d-cell-culture-platform-for-enhanced-drug-discovery-and-precision-medicine 2025-09-20T01:12:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-biomed-launches-a-perfusctm-3d-cell-culture-platform-for-enhanced-drug-discovery-and-precision-medicine 2025-09-20T01:12:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-hdt-bio-s-first-in-class-hdt-321-for-crimean-congo-hemorrhagic-fever-prevention 2025-09-19T21:14:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-hdt-bio-s-first-in-class-hdt-321-for-crimean-congo-hemorrhagic-fever-prevention 2025-09-19T21:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/six-year-upadacitinib-safety-data-shows-comparable-cardiovascular-risk-in-atopic-dermatitis-patients 2025-09-19T21:13:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/six-year-upadacitinib-safety-data-shows-comparable-cardiovascular-risk-in-atopic-dermatitis-patients 2025-09-19T21:13:56+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-challenges-regeneron-s-high-dose-aflibercept-patent-in-post-grant-review 2025-09-19T21:13:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alvotech-challenges-regeneron-s-high-dose-aflibercept-patent-in-post-grant-review 2025-09-19T21:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-amgen-s-uplizna-for-rare-autoimmune-disease-igg4-rd 2025-09-19T21:11:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-recommends-amgen-s-uplizna-for-rare-autoimmune-disease-igg4-rd 2025-09-19T21:11:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-subcutaneous-pembrolizumab-formulation-for-solid-tumors-reducing-treatment-time-by-nearly-50 2025-09-19T21:10:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-subcutaneous-pembrolizumab-formulation-for-solid-tumors-reducing-treatment-time-by-nearly-50 2025-09-19T21:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/r-pharm-presents-long-term-olokizumab-data-showing-sustained-improvement-in-rheumatoid-arthritis-patients 2025-09-19T17:20:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/r-pharm-presents-long-term-olokizumab-data-showing-sustained-improvement-in-rheumatoid-arthritis-patients 2025-09-19T17:20:38+00:00 hourly 0.9 https://trial.medpath.com/news/curateq-biologics-completes-successful-phase-3-trial-for-denosumab-biosimilar-in-postmenopausal-osteoporosis 2025-09-19T17:20:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curateq-biologics-completes-successful-phase-3-trial-for-denosumab-biosimilar-in-postmenopausal-osteoporosis 2025-09-19T17:20:06+00:00 hourly 0.9 https://trial.medpath.com/news/elicera-therapeutics-faces-u-s-patent-setback-for-itank-car-t-enhancement-platform 2025-09-19T17:19:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elicera-therapeutics-faces-u-s-patent-setback-for-itank-car-t-enhancement-platform 2025-09-19T17:19:22+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-receives-japanese-approval-for-nexletol-as-novel-non-statin-cholesterol-treatment 2025-09-19T17:19:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/otsuka-receives-japanese-approval-for-nexletol-as-novel-non-statin-cholesterol-treatment 2025-09-19T17:19:17+00:00 hourly 0.9 https://trial.medpath.com/news/bluebird-bio-rebrands-as-genetix-biotherapeutics-following-private-buyout-refocuses-on-gene-therapy-access 2025-09-19T17:18:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bluebird-bio-rebrands-as-genetix-biotherapeutics-following-private-buyout-refocuses-on-gene-therapy-access 2025-09-19T17:18:37+00:00 hourly 0.9 https://trial.medpath.com/news/eckert-ziegler-receives-japanese-approval-for-galliapharm-r-generator-expanding-gallium-68-diagnostics-for-prostate-cancer 2025-09-19T17:18:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eckert-ziegler-receives-japanese-approval-for-galliapharm-r-generator-expanding-gallium-68-diagnostics-for-prostate-cancer 2025-09-19T17:18:20+00:00 hourly 0.9 https://trial.medpath.com/news/tecvayli-and-darzalex-faspro-combination-achieves-100-mrd-negativity-in-newly-diagnosed-multiple-myeloma-patients 2025-09-19T17:17:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tecvayli-and-darzalex-faspro-combination-achieves-100-mrd-negativity-in-newly-diagnosed-multiple-myeloma-patients 2025-09-19T17:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/precision-biologics-reports-promising-efficacy-data-for-novel-ovarian-cancer-adc-pb-vcmmae-5 2025-09-19T17:16:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-biologics-reports-promising-efficacy-data-for-novel-ovarian-cancer-adc-pb-vcmmae-5 2025-09-19T17:16:21+00:00 hourly 0.9 https://trial.medpath.com/news/lexaria-s-dehydratech-technology-enhances-semaglutide-brain-delivery-in-preclinical-study 2025-09-19T17:15:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexaria-s-dehydratech-technology-enhances-semaglutide-brain-delivery-in-preclinical-study 2025-09-19T17:15:18+00:00 hourly 0.9 https://trial.medpath.com/news/indoco-remedies-achieves-zero-fda-observations-at-mumbai-api-manufacturing-facility 2025-09-19T17:15:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indoco-remedies-achieves-zero-fda-observations-at-mumbai-api-manufacturing-facility 2025-09-19T17:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-secures-japanese-approval-for-three-biosimilars-including-first-global-golimumab-biosimilar 2025-09-19T17:14:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alvotech-secures-japanese-approval-for-three-biosimilars-including-first-global-golimumab-biosimilar 2025-09-19T17:14:35+00:00 hourly 0.9 https://trial.medpath.com/news/kindeva-opens-150000-sq-ft-uk-facility-to-develop-environmentally-friendly-inhaler-propellants 2025-09-19T17:14:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kindeva-opens-150000-sq-ft-uk-facility-to-develop-environmentally-friendly-inhaler-propellants 2025-09-19T17:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/european-regulators-recommend-approval-for-novo-nordisk-s-weekly-diabetes-combination-therapy-kyinsu 2025-09-19T17:12:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-regulators-recommend-approval-for-novo-nordisk-s-weekly-diabetes-combination-therapy-kyinsu 2025-09-19T17:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-medtronic-s-altaviva-implantable-device-for-urge-urinary-incontinence 2025-09-19T17:11:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-medtronic-s-altaviva-implantable-device-for-urge-urinary-incontinence 2025-09-19T17:11:50+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-s-bylvay-receives-japanese-approval-for-rare-liver-disease-pfic-offering-first-non-surgical-treatment-option 2025-09-19T17:11:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-s-bylvay-receives-japanese-approval-for-rare-liver-disease-pfic-offering-first-non-surgical-treatment-option 2025-09-19T17:11:02+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-clinical-trials-demonstrate-efficacy-of-il-13-and-il-4-il-13-inhibitors-in-patients-with-darker-skin-tones 2025-09-19T17:10:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-clinical-trials-demonstrate-efficacy-of-il-13-and-il-4-il-13-inhibitors-in-patients-with-darker-skin-tones 2025-09-19T17:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/datavant-and-indegene-partner-to-accelerate-clinical-trial-recruitment-for-rare-diseases 2025-09-19T17:10:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/datavant-and-indegene-partner-to-accelerate-clinical-trial-recruitment-for-rare-diseases 2025-09-19T17:10:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-early-alert-for-abbott-s-tactiflex-ablation-catheter-following-tip-detachment-reports 2025-09-19T13:13:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-early-alert-for-abbott-s-tactiflex-ablation-catheter-following-tip-detachment-reports 2025-09-19T13:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/genflow-biosciences-files-patent-examination-request-in-china-for-sirt6-based-nash-therapy 2025-09-19T13:12:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genflow-biosciences-files-patent-examination-request-in-china-for-sirt6-based-nash-therapy 2025-09-19T13:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/ema-approves-first-treatment-for-non-cystic-fibrosis-bronchiectasis-as-16-new-medicines-receive-marketing-authorization 2025-09-19T13:11:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-approves-first-treatment-for-non-cystic-fibrosis-bronchiectasis-as-16-new-medicines-receive-marketing-authorization 2025-09-19T13:11:27+00:00 hourly 0.9 https://trial.medpath.com/news/ql-biopharm-s-zovaglutide-achieves-13-8-weight-loss-with-monthly-dosing-in-phase-2-trial 2025-09-19T13:11:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ql-biopharm-s-zovaglutide-achieves-13-8-weight-loss-with-monthly-dosing-in-phase-2-trial 2025-09-19T13:11:04+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-receives-japanese-approval-for-tecentriq-in-rare-lymphoma-marking-first-checkpoint-inhibitor-for-enkl 2025-09-19T13:10:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-receives-japanese-approval-for-tecentriq-in-rare-lymphoma-marking-first-checkpoint-inhibitor-for-enkl 2025-09-19T13:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/vitamin-b3-derivative-shows-54-reduction-in-skin-cancer-risk-in-large-veterans-study 2025-09-19T09:15:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vitamin-b3-derivative-shows-54-reduction-in-skin-cancer-risk-in-large-veterans-study 2025-09-19T09:15:02+00:00 hourly 0.9 https://trial.medpath.com/news/iaso-biotherapeutics-reports-sustained-36-month-efficacy-data-for-fucaso-car-t-therapy-in-multiple-myeloma 2025-09-19T09:14:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iaso-biotherapeutics-reports-sustained-36-month-efficacy-data-for-fucaso-car-t-therapy-in-multiple-myeloma 2025-09-19T09:14:41+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-liver-cancer-pipeline-shows-robust-growth-with-50-companies-developing-novel-therapies 2025-09-19T09:12:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-liver-cancer-pipeline-shows-robust-growth-with-50-companies-developing-novel-therapies 2025-09-19T09:12:30+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-targets-7-billion-global-biosimilar-market-with-fda-approved-denosumab-products 2025-09-19T09:11:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-biologics-targets-7-billion-global-biosimilar-market-with-fda-approved-denosumab-products 2025-09-19T09:11:29+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-advisory-panel-votes-to-limit-combined-mmrv-vaccine-use-in-young-children-due-to-seizure-risk 2025-09-19T09:10:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-advisory-panel-votes-to-limit-combined-mmrv-vaccine-use-in-young-children-due-to-seizure-risk 2025-09-19T09:10:33+00:00 hourly 0.9 https://trial.medpath.com/news/kane-biotech-submits-fda-510-k-application-for-third-revyve-wound-care-product 2025-09-19T05:14:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kane-biotech-submits-fda-510-k-application-for-third-revyve-wound-care-product 2025-09-19T05:14:59+00:00 hourly 0.9 https://trial.medpath.com/news/sight-sciences-omni-system-gains-unitedhealthcare-coverage-as-meta-analysis-confirms-long-term-efficacy-in-glaucoma-treatment 2025-09-19T05:14:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sight-sciences-omni-system-gains-unitedhealthcare-coverage-as-meta-analysis-confirms-long-term-efficacy-in-glaucoma-treatment 2025-09-19T05:14:31+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-advisory-committee-narrows-mmrv-vaccine-recommendations-signals-potential-changes-to-covid-19-and-hepatitis-b-guidelines 2025-09-19T05:14:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-advisory-committee-narrows-mmrv-vaccine-recommendations-signals-potential-changes-to-covid-19-and-hepatitis-b-guidelines 2025-09-19T05:14:28+00:00 hourly 0.9 https://trial.medpath.com/news/exsight-ventures-backs-revopsis-therapeutics-novel-tri-specific-antibody-platform-for-retinal-diseases 2025-09-19T05:11:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exsight-ventures-backs-revopsis-therapeutics-novel-tri-specific-antibody-platform-for-retinal-diseases 2025-09-19T05:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/genedx-strengthens-leadership-team-with-key-appointments-to-advance-ai-powered-precision-medicine 2025-09-19T05:09:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genedx-strengthens-leadership-team-with-key-appointments-to-advance-ai-powered-precision-medicine 2025-09-19T05:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/aurora-spine-launches-world-s-first-bone-density-matched-spinal-implant-for-lumbar-fusion 2025-09-19T05:09:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurora-spine-launches-world-s-first-bone-density-matched-spinal-implant-for-lumbar-fusion 2025-09-19T05:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/low-dose-antithymocyte-globulin-shows-promise-for-type-1-diabetes-treatment-in-youth 2025-09-19T01:14:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/low-dose-antithymocyte-globulin-shows-promise-for-type-1-diabetes-treatment-in-youth 2025-09-19T01:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/roche-acquires-89bio-to-expand-cardiometabolic-pipeline-beyond-glp-1-competition 2025-09-19T01:14:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-acquires-89bio-to-expand-cardiometabolic-pipeline-beyond-glp-1-competition 2025-09-19T01:14:07+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-settles-patent-dispute-with-alnylam-over-covid-19-vaccine-technology 2025-09-19T01:13:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-settles-patent-dispute-with-alnylam-over-covid-19-vaccine-technology 2025-09-19T01:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/cevostamab-consolidation-after-car-t-therapy-shows-93-mrd-negative-response-rate-in-heavily-pretreated-multiple-myeloma 2025-09-19T01:13:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cevostamab-consolidation-after-car-t-therapy-shows-93-mrd-negative-response-rate-in-heavily-pretreated-multiple-myeloma 2025-09-19T01:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-secures-italian-reimbursement-for-crispr-gene-therapy-casgevy-expanding-european-access-for-blood-disorders 2025-09-19T01:12:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-secures-italian-reimbursement-for-crispr-gene-therapy-casgevy-expanding-european-access-for-blood-disorders 2025-09-19T01:12:02+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-stocks-surge-after-hours-as-investors-anticipate-key-clinical-trial-results 2025-09-19T01:11:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-stocks-surge-after-hours-as-investors-anticipate-key-clinical-trial-results 2025-09-19T01:11:41+00:00 hourly 0.9 https://trial.medpath.com/news/weill-cornell-medicine-receives-20-8-million-nih-grant-to-develop-childhood-hiv-vaccine 2025-09-19T01:10:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weill-cornell-medicine-receives-20-8-million-nih-grant-to-develop-childhood-hiv-vaccine 2025-09-19T01:10:34+00:00 hourly 0.9 https://trial.medpath.com/news/gerd-pipeline-shows-promise-with-novel-p-cab-therapies-advancing-through-late-stage-trials 2025-09-19T01:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gerd-pipeline-shows-promise-with-novel-p-cab-therapies-advancing-through-late-stage-trials 2025-09-19T01:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/mink-therapeutics-appoints-dr-terese-hammond-to-lead-inkt-cell-therapy-pipeline-toward-pivotal-trials 2025-09-18T21:19:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mink-therapeutics-appoints-dr-terese-hammond-to-lead-inkt-cell-therapy-pipeline-toward-pivotal-trials 2025-09-18T21:19:21+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-launches-first-omalizumab-biosimilar-omlyclo-in-europe-starting-with-norway 2025-09-18T21:17:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-launches-first-omalizumab-biosimilar-omlyclo-in-europe-starting-with-norway 2025-09-18T21:17:14+00:00 hourly 0.9 https://trial.medpath.com/news/nt-301-nasal-spray-shows-promising-phase-1-results-for-parkinson-s-disease-off-episodes 2025-09-18T21:14:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nt-301-nasal-spray-shows-promising-phase-1-results-for-parkinson-s-disease-off-episodes 2025-09-18T21:14:16+00:00 hourly 0.9 https://trial.medpath.com/news/trevi-therapeutics-presents-nalbuphine-er-data-at-major-respiratory-conferences-following-positive-phase-2-trials 2025-09-18T21:14:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trevi-therapeutics-presents-nalbuphine-er-data-at-major-respiratory-conferences-following-positive-phase-2-trials 2025-09-18T21:14:13+00:00 hourly 0.9 https://trial.medpath.com/news/vectory-therapeutics-secures-1-2b-deal-for-shape-s-brain-penetrant-aav-capsid-technology 2025-09-18T21:13:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vectory-therapeutics-secures-1-2b-deal-for-shape-s-brain-penetrant-aav-capsid-technology 2025-09-18T21:13:28+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-demonstrates-promise-as-one-time-treatment-for-alpha-thalassemia 2025-09-18T21:13:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-demonstrates-promise-as-one-time-treatment-for-alpha-thalassemia 2025-09-18T21:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/med-safety-mobile-app-increases-adverse-drug-reaction-reporting-by-73-in-uganda-trial 2025-09-18T21:13:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/med-safety-mobile-app-increases-adverse-drug-reaction-reporting-by-73-in-uganda-trial 2025-09-18T21:13:12+00:00 hourly 0.9 https://trial.medpath.com/news/formation-bio-strengthens-leadership-team-with-former-pfizer-and-benevolentai-executives-to-advance-ai-driven-drug-development 2025-09-18T21:11:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formation-bio-strengthens-leadership-team-with-former-pfizer-and-benevolentai-executives-to-advance-ai-driven-drug-development 2025-09-18T21:11:31+00:00 hourly 0.9 https://trial.medpath.com/news/kelyniam-global-receives-first-fda-clearance-for-bcp-peek-cranial-implants-in-eight-years 2025-09-18T21:09:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kelyniam-global-receives-first-fda-clearance-for-bcp-peek-cranial-implants-in-eight-years 2025-09-18T21:09:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-hydrogen-peroxide-use-in-food-production-opening-new-market-for-tomi-s-steramist-technology 2025-09-18T21:09:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-hydrogen-peroxide-use-in-food-production-opening-new-market-for-tomi-s-steramist-technology 2025-09-18T21:09:50+00:00 hourly 0.9 https://trial.medpath.com/news/stryker-opens-140000-square-foot-r-d-innovation-center-in-bengaluru-to-advance-medical-technology 2025-09-18T20:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stryker-opens-140000-square-foot-r-d-innovation-center-in-bengaluru-to-advance-medical-technology 2025-09-18T20:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/early-hormone-therapy-reduces-alzheimer-s-risk-by-32-in-postmenopausal-women-new-meta-analysis-shows 2025-09-18T19:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-hormone-therapy-reduces-alzheimer-s-risk-by-32-in-postmenopausal-women-new-meta-analysis-shows 2025-09-18T19:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/iveena-secures-2-million-nih-grant-to-advance-first-in-class-pediatric-myopia-eye-drop 2025-09-18T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iveena-secures-2-million-nih-grant-to-advance-first-in-class-pediatric-myopia-eye-drop 2025-09-18T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/semaglutide-demonstrates-significant-metabolic-benefits-in-schizophrenia-patients-on-antipsychotic-therapy 2025-09-18T17:21:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/semaglutide-demonstrates-significant-metabolic-benefits-in-schizophrenia-patients-on-antipsychotic-therapy 2025-09-18T17:21:31+00:00 hourly 0.9 https://trial.medpath.com/news/merck-invests-eur150-million-in-advanced-filtration-manufacturing-facility-in-ireland 2025-09-18T17:21:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-invests-eur150-million-in-advanced-filtration-manufacturing-facility-in-ireland 2025-09-18T17:21:24+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-drug-delivery-technologies-drive-biotech-innovation-as-nanomedicine-market-approaches-430-billion 2025-09-18T17:21:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-drug-delivery-technologies-drive-biotech-innovation-as-nanomedicine-market-approaches-430-billion 2025-09-18T17:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/geneos-therapeutics-reports-five-year-recurrence-free-survival-in-aggressive-brain-and-liver-cancer-patients-with-personalized-immunotherapy 2025-09-18T17:19:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geneos-therapeutics-reports-five-year-recurrence-free-survival-in-aggressive-brain-and-liver-cancer-patients-with-personalized-immunotherapy 2025-09-18T17:19:23+00:00 hourly 0.9 https://trial.medpath.com/news/cullgen-completes-phase-1-enrollment-for-novel-non-opioid-pain-therapy-cg001419 2025-09-18T17:18:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cullgen-completes-phase-1-enrollment-for-novel-non-opioid-pain-therapy-cg001419 2025-09-18T17:18:38+00:00 hourly 0.9 https://trial.medpath.com/news/nkgen-biotech-to-present-troculeucel-clinical-data-for-alzheimer-s-disease-at-major-international-conferences 2025-09-18T17:17:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nkgen-biotech-to-present-troculeucel-clinical-data-for-alzheimer-s-disease-at-major-international-conferences 2025-09-18T17:17:25+00:00 hourly 0.9 https://trial.medpath.com/news/atai-life-sciences-secures-11-4-million-nih-grant-for-non-hallucinogenic-opioid-use-disorder-treatment 2025-09-18T17:16:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atai-life-sciences-secures-11-4-million-nih-grant-for-non-hallucinogenic-opioid-use-disorder-treatment 2025-09-18T17:16:28+00:00 hourly 0.9 https://trial.medpath.com/news/humacyte-plans-q4-ind-filing-for-coronary-tissue-engineered-vessel-following-promising-primate-study 2025-09-18T17:15:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/humacyte-plans-q4-ind-filing-for-coronary-tissue-engineered-vessel-following-promising-primate-study 2025-09-18T17:15:32+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-acquires-alcyone-therapeutics-for-85m-to-advance-implantable-drug-delivery-system-for-neurological-therapies 2025-09-18T17:14:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-acquires-alcyone-therapeutics-for-85m-to-advance-implantable-drug-delivery-system-for-neurological-therapies 2025-09-18T17:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/argenx-expands-partnership-with-fujifilm-biotechnologies-to-manufacture-efgartigimod-in-the-u-s 2025-09-18T17:13:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/argenx-expands-partnership-with-fujifilm-biotechnologies-to-manufacture-efgartigimod-in-the-u-s 2025-09-18T17:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/alk-partners-with-gensci-to-overcome-chinese-regulatory-challenges-and-expand-into-immunotherapy 2025-09-18T17:13:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alk-partners-with-gensci-to-overcome-chinese-regulatory-challenges-and-expand-into-immunotherapy 2025-09-18T17:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/alnylam-pharmaceuticals-joins-alliance-for-genomic-discovery-to-accelerate-rnai-drug-development 2025-09-18T17:12:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alnylam-pharmaceuticals-joins-alliance-for-genomic-discovery-to-accelerate-rnai-drug-development 2025-09-18T17:12:14+00:00 hourly 0.9 https://trial.medpath.com/news/organox-receives-fda-approval-for-air-transport-of-liver-perfusion-device-expanding-transplant-access-nationwide 2025-09-18T17:12:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/organox-receives-fda-approval-for-air-transport-of-liver-perfusion-device-expanding-transplant-access-nationwide 2025-09-18T17:12:09+00:00 hourly 0.9 https://trial.medpath.com/news/hong-kong-introduces-fast-track-drug-approval-system-to-reduce-review-time-by-33 2025-09-18T17:11:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hong-kong-introduces-fast-track-drug-approval-system-to-reduce-review-time-by-33 2025-09-18T17:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/marengo-therapeutics-advances-phase-2-expansion-of-invikafusp-alfa-trodelvy-combination-for-metastatic-breast-cancer 2025-09-18T17:11:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marengo-therapeutics-advances-phase-2-expansion-of-invikafusp-alfa-trodelvy-combination-for-metastatic-breast-cancer 2025-09-18T17:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-three-novel-hae-therapies-in-2025-ending-four-year-regulatory-drought 2025-09-18T17:11:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-three-novel-hae-therapies-in-2025-ending-four-year-regulatory-drought 2025-09-18T17:11:34+00:00 hourly 0.9 https://trial.medpath.com/news/brainlab-receives-fda-clearance-for-spine-mixed-reality-navigation-system 2025-09-18T17:11:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brainlab-receives-fda-clearance-for-spine-mixed-reality-navigation-system 2025-09-18T17:11:27+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-drugmaker-jiangsu-hengrui-becomes-world-s-top-clinical-trial-sponsor-as-china-transforms-global-r-d-landscape 2025-09-18T17:10:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-drugmaker-jiangsu-hengrui-becomes-world-s-top-clinical-trial-sponsor-as-china-transforms-global-r-d-landscape 2025-09-18T17:10:55+00:00 hourly 0.9 https://trial.medpath.com/news/closed-loop-medicine-launches-first-personalized-glp-1-dosing-platform-to-combat-high-discontinuation-rates 2025-09-18T17:10:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/closed-loop-medicine-launches-first-personalized-glp-1-dosing-platform-to-combat-high-discontinuation-rates 2025-09-18T17:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/mavenclad-shows-sustained-long-term-benefits-in-multiple-sclerosis-with-four-year-data-at-ectrims-2025 2025-09-18T13:13:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mavenclad-shows-sustained-long-term-benefits-in-multiple-sclerosis-with-four-year-data-at-ectrims-2025 2025-09-18T13:13:58+00:00 hourly 0.9 https://trial.medpath.com/news/ovation-science-and-skinvisible-expand-thc-v-partnership-for-obesity-treatment-with-novel-transdermal-delivery-technology 2025-09-18T13:11:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ovation-science-and-skinvisible-expand-thc-v-partnership-for-obesity-treatment-with-novel-transdermal-delivery-technology 2025-09-18T13:11:32+00:00 hourly 0.9 https://trial.medpath.com/news/immuto-scientific-secures-8m-funding-and-daiichi-sankyo-partnership-to-advance-ai-driven-cancer-target-discovery 2025-09-18T13:10:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuto-scientific-secures-8m-funding-and-daiichi-sankyo-partnership-to-advance-ai-driven-cancer-target-discovery 2025-09-18T13:10:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-updated-airsupra-label-showing-46-reduction-in-asthma-attacks-for-mild-asthma-patients 2025-09-18T13:09:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-updated-airsupra-label-showing-46-reduction-in-asthma-attacks-for-mild-asthma-patients 2025-09-18T13:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/biocardia-s-cardiamp-cell-therapy-shows-82-reduction-in-angina-episodes-in-chronic-myocardial-ischemia-trial 2025-09-18T13:09:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocardia-s-cardiamp-cell-therapy-shows-82-reduction-in-angina-episodes-in-chronic-myocardial-ischemia-trial 2025-09-18T13:09:53+00:00 hourly 0.9 https://trial.medpath.com/news/roche-acquires-89bio-for-3-5-billion-to-strengthen-mash-treatment-pipeline 2025-09-18T13:09:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-acquires-89bio-for-3-5-billion-to-strengthen-mash-treatment-pipeline 2025-09-18T13:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/greenwich-lifesciences-expands-flamingo-01-breast-cancer-trial-to-ireland-adding-to-global-network-of-150-sites 2025-09-18T13:09:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greenwich-lifesciences-expands-flamingo-01-breast-cancer-trial-to-ireland-adding-to-global-network-of-150-sites 2025-09-18T13:09:29+00:00 hourly 0.9 https://trial.medpath.com/news/cphi-frankfurt-2025-reveals-pharma-awards-finalists-highlighting-industry-innovation-and-sustainability 2025-09-18T10:51:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cphi-frankfurt-2025-reveals-pharma-awards-finalists-highlighting-industry-innovation-and-sustainability 2025-09-18T10:51:13+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-s-brain-mechanism-revealed-after-60-years-new-pathway-could-transform-diabetes-treatment 2025-09-18T09:09:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metformin-s-brain-mechanism-revealed-after-60-years-new-pathway-could-transform-diabetes-treatment 2025-09-18T09:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/st-jude-researchers-develop-novel-combination-therapy-to-overcome-neuroblastoma-treatment-resistance 2025-09-18T09:09:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/st-jude-researchers-develop-novel-combination-therapy-to-overcome-neuroblastoma-treatment-resistance 2025-09-18T09:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-s-galvokimig-shows-promise-in-phase-1-2a-trial-for-moderate-to-severe-atopic-dermatitis 2025-09-18T09:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-s-galvokimig-shows-promise-in-phase-1-2a-trial-for-moderate-to-severe-atopic-dermatitis 2025-09-18T09:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/portuguese-startup-mondego-bio-secures-series-a-funding-to-develop-novel-ptpn2-inhibitors-for-cancer-immunotherapy 2025-09-18T09:09:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/portuguese-startup-mondego-bio-secures-series-a-funding-to-develop-novel-ptpn2-inhibitors-for-cancer-immunotherapy 2025-09-18T09:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-test-predicts-semaglutide-response-in-post-bariatric-surgery-patients 2025-09-18T09:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-test-predicts-semaglutide-response-in-post-bariatric-surgery-patients 2025-09-18T09:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/corestemchemon-s-neuronata-r-shows-significant-benefits-in-als-slow-progressors-in-phase-3-trial 2025-09-18T09:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corestemchemon-s-neuronata-r-shows-significant-benefits-in-als-slow-progressors-in-phase-3-trial 2025-09-18T09:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/cocoa-extract-supplements-reduce-key-inflammatory-marker-in-large-clinical-trial 2025-09-18T05:11:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cocoa-extract-supplements-reduce-key-inflammatory-marker-in-large-clinical-trial 2025-09-18T05:11:41+00:00 hourly 0.9 https://trial.medpath.com/news/stryker-and-siemens-healthineers-partner-to-develop-robotic-neurovascular-system-for-stroke-and-aneurysm-treatment 2025-09-18T05:10:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stryker-and-siemens-healthineers-partner-to-develop-robotic-neurovascular-system-for-stroke-and-aneurysm-treatment 2025-09-18T05:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/carsgen-s-zevor-cel-shows-exceptional-5-year-survival-data-in-relapsed-multiple-myeloma-patients 2025-09-18T05:09:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carsgen-s-zevor-cel-shows-exceptional-5-year-survival-data-in-relapsed-multiple-myeloma-patients 2025-09-18T05:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reversal-threatens-access-to-promising-duchenne-muscular-dystrophy-cell-therapy 2025-09-18T05:09:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-reversal-threatens-access-to-promising-duchenne-muscular-dystrophy-cell-therapy 2025-09-18T05:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/nanobiotix-s-jnj-1900-shows-promising-results-in-anti-pd-1-resistant-melanoma-patients 2025-09-18T01:18:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanobiotix-s-jnj-1900-shows-promising-results-in-anti-pd-1-resistant-melanoma-patients 2025-09-18T01:18:14+00:00 hourly 0.9 https://trial.medpath.com/news/magicrna-s-in-vivo-car-t-therapy-hn2301-shows-promise-in-first-in-human-lupus-trial 2025-09-18T01:13:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/magicrna-s-in-vivo-car-t-therapy-hn2301-shows-promise-in-first-in-human-lupus-trial 2025-09-18T01:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/arsenal-biosciences-cuts-50-of-workforce-despite-325m-series-c-funding-round 2025-09-18T01:12:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arsenal-biosciences-cuts-50-of-workforce-despite-325m-series-c-funding-round 2025-09-18T01:12:22+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-advisory-panel-delays-controversial-vote-on-newborn-hepatitis-b-vaccine-timing 2025-09-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-advisory-panel-delays-controversial-vote-on-newborn-hepatitis-b-vaccine-timing 2025-09-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-lamotrigine-oral-suspension-for-epilepsy-and-bipolar-disorder-treatment 2025-09-17T23:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-lamotrigine-oral-suspension-for-epilepsy-and-bipolar-disorder-treatment 2025-09-17T23:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/chronic-lower-back-pain-pipeline-shows-mixed-results-as-multiple-phase-iii-trials-report-outcomes 2025-09-17T21:19:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chronic-lower-back-pain-pipeline-shows-mixed-results-as-multiple-phase-iii-trials-report-outcomes 2025-09-17T21:19:06+00:00 hourly 0.9 https://trial.medpath.com/news/crown-bioscience-opens-advanced-oncology-model-development-center-in-north-carolina 2025-09-17T21:16:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crown-bioscience-opens-advanced-oncology-model-development-center-in-north-carolina 2025-09-17T21:16:11+00:00 hourly 0.9 https://trial.medpath.com/news/swiss-researchers-develop-dual-action-fusion-protein-for-enhanced-cancer-immunotherapy 2025-09-17T21:15:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swiss-researchers-develop-dual-action-fusion-protein-for-enhanced-cancer-immunotherapy 2025-09-17T21:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/elranatamab-consolidation-therapy-shows-promise-in-deepening-response-after-car-t-treatment-in-multiple-myeloma 2025-09-17T21:15:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elranatamab-consolidation-therapy-shows-promise-in-deepening-response-after-car-t-treatment-in-multiple-myeloma 2025-09-17T21:15:10+00:00 hourly 0.9 https://trial.medpath.com/news/eribulin-pyrotinib-combination-shows-promise-in-trastuzumab-resistant-her2-breast-cancer 2025-09-17T21:14:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eribulin-pyrotinib-combination-shows-promise-in-trastuzumab-resistant-her2-breast-cancer 2025-09-17T21:14:52+00:00 hourly 0.9 https://trial.medpath.com/news/wheeler-bio-partners-with-mindimmune-to-advance-first-in-class-alzheimer-s-therapy-miti-101 2025-09-17T21:14:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wheeler-bio-partners-with-mindimmune-to-advance-first-in-class-alzheimer-s-therapy-miti-101 2025-09-17T21:14:39+00:00 hourly 0.9 https://trial.medpath.com/news/oruka-therapeutics-orka-001-shows-100-day-half-life-in-phase-1-trial-potentially-enabling-annual-dosing-for-psoriasis 2025-09-17T21:13:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oruka-therapeutics-orka-001-shows-100-day-half-life-in-phase-1-trial-potentially-enabling-annual-dosing-for-psoriasis 2025-09-17T21:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/changchun-high-tech-secures-eur177-7-million-deal-for-alk-s-house-dust-mite-allergy-immunotherapies-in-china 2025-09-17T21:13:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/changchun-high-tech-secures-eur177-7-million-deal-for-alk-s-house-dust-mite-allergy-immunotherapies-in-china 2025-09-17T21:13:19+00:00 hourly 0.9 https://trial.medpath.com/news/bio-protocol-raises-6-9m-to-launch-ai-native-decentralized-science-platform-for-drug-discovery 2025-09-17T21:13:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bio-protocol-raises-6-9m-to-launch-ai-native-decentralized-science-platform-for-drug-discovery 2025-09-17T21:13:08+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-receives-fda-breakthrough-therapy-designation-for-r-dxd-in-ovarian-cancer 2025-09-17T21:12:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daiichi-sankyo-receives-fda-breakthrough-therapy-designation-for-r-dxd-in-ovarian-cancer 2025-09-17T21:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/arthex-biotech-secures-87m-series-b-to-advance-novel-rna-therapy-for-myotonic-dystrophy-type-1 2025-09-17T21:09:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arthex-biotech-secures-87m-series-b-to-advance-novel-rna-therapy-for-myotonic-dystrophy-type-1 2025-09-17T21:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/rgenta-therapeutics-receives-fda-orphan-drug-designation-for-rgt-61159-in-adenoid-cystic-carcinoma-treatment 2025-09-17T17:23:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rgenta-therapeutics-receives-fda-orphan-drug-designation-for-rgt-61159-in-adenoid-cystic-carcinoma-treatment 2025-09-17T17:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/nurix-and-gilead-s-irak4-degrader-gs-6791-shows-promise-for-inflammatory-skin-diseases-in-preclinical-studies 2025-09-17T17:22:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nurix-and-gilead-s-irak4-degrader-gs-6791-shows-promise-for-inflammatory-skin-diseases-in-preclinical-studies 2025-09-17T17:22:13+00:00 hourly 0.9 https://trial.medpath.com/news/character-biosciences-secures-110m-series-b-extension-expands-leadership-to-advance-amd-therapeutics 2025-09-17T17:21:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/character-biosciences-secures-110m-series-b-extension-expands-leadership-to-advance-amd-therapeutics 2025-09-17T17:21:49+00:00 hourly 0.9 https://trial.medpath.com/news/enveric-biosciences-publishes-breakthrough-research-on-microbial-bioproduction-of-neuropsychiatric-compounds 2025-09-17T17:20:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enveric-biosciences-publishes-breakthrough-research-on-microbial-bioproduction-of-neuropsychiatric-compounds 2025-09-17T17:20:47+00:00 hourly 0.9 https://trial.medpath.com/news/tatum-bioscience-s-nanofilament-immunotherapy-tat003-demonstrates-strong-antitumor-activity-in-preclinical-study 2025-09-17T17:16:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tatum-bioscience-s-nanofilament-immunotherapy-tat003-demonstrates-strong-antitumor-activity-in-preclinical-study 2025-09-17T17:16:04+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-s-garetosmab-achieves-90-reduction-in-bone-formation-in-rare-disease-trial 2025-09-17T17:15:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-s-garetosmab-achieves-90-reduction-in-bone-formation-in-rare-disease-trial 2025-09-17T17:15:57+00:00 hourly 0.9 https://trial.medpath.com/news/askbio-completes-enrollment-in-phase-1-gene-therapy-trial-for-rare-neurological-disease-msa-p 2025-09-17T17:15:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/askbio-completes-enrollment-in-phase-1-gene-therapy-trial-for-rare-neurological-disease-msa-p 2025-09-17T17:15:43+00:00 hourly 0.9 https://trial.medpath.com/news/leo-pharma-s-temtokibart-meets-primary-endpoint-in-phase-2b-atopic-dermatitis-trial 2025-09-17T17:15:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leo-pharma-s-temtokibart-meets-primary-endpoint-in-phase-2b-atopic-dermatitis-trial 2025-09-17T17:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/luxa-biotechnology-reports-significant-vision-gains-in-first-in-human-stem-cell-trial-for-dry-amd 2025-09-17T17:14:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/luxa-biotechnology-reports-significant-vision-gains-in-first-in-human-stem-cell-trial-for-dry-amd 2025-09-17T17:14:44+00:00 hourly 0.9 https://trial.medpath.com/news/mapi-pharma-initiates-phase-i-ii-trial-for-once-monthly-cariprazine-depot-injection 2025-09-17T17:14:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mapi-pharma-initiates-phase-i-ii-trial-for-once-monthly-cariprazine-depot-injection 2025-09-17T17:14:13+00:00 hourly 0.9 https://trial.medpath.com/news/arch-biopartners-acquires-novel-il-32-platform-for-chronic-kidney-disease-treatment 2025-09-17T17:13:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arch-biopartners-acquires-novel-il-32-platform-for-chronic-kidney-disease-treatment 2025-09-17T17:13:37+00:00 hourly 0.9 https://trial.medpath.com/news/visionary-holdings-partners-with-yike-regenerative-medicine-to-advance-anti-aging-biotechnology 2025-09-17T17:13:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/visionary-holdings-partners-with-yike-regenerative-medicine-to-advance-anti-aging-biotechnology 2025-09-17T17:13:34+00:00 hourly 0.9 https://trial.medpath.com/news/purdue-pharma-s-tinostamustine-enters-phase-2-3-gbm-agile-trial-for-glioblastoma-treatment 2025-09-17T17:12:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/purdue-pharma-s-tinostamustine-enters-phase-2-3-gbm-agile-trial-for-glioblastoma-treatment 2025-09-17T17:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/ollin-biosciences-emerges-with-100m-to-challenge-leading-eye-disease-treatments 2025-09-17T17:11:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ollin-biosciences-emerges-with-100m-to-challenge-leading-eye-disease-treatments 2025-09-17T17:11:07+00:00 hourly 0.9 https://trial.medpath.com/news/mabwell-and-aditum-bio-launch-kalexo-bio-to-advance-novel-sirna-therapy-for-cardiovascular-disease 2025-09-17T17:10:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabwell-and-aditum-bio-launch-kalexo-bio-to-advance-novel-sirna-therapy-for-cardiovascular-disease 2025-09-17T17:10:58+00:00 hourly 0.9 https://trial.medpath.com/news/first-digital-cbt-therapeutic-for-menopause-shows-significant-symptom-reduction-in-clinical-trial 2025-09-17T17:10:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-digital-cbt-therapeutic-for-menopause-shows-significant-symptom-reduction-in-clinical-trial 2025-09-17T17:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-drugs-alter-taste-perception-enhancing-sweetness-and-saltiness-to-support-appetite-control 2025-09-17T13:14:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-drugs-alter-taste-perception-enhancing-sweetness-and-saltiness-to-support-appetite-control 2025-09-17T13:14:14+00:00 hourly 0.9 https://trial.medpath.com/news/navigator-medicines-reports-positive-phase-1a-safety-data-for-dual-target-bispecific-antibody-nav-240 2025-09-17T13:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/navigator-medicines-reports-positive-phase-1a-safety-data-for-dual-target-bispecific-antibody-nav-240 2025-09-17T13:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/brepocitinib-achieves-first-ever-positive-phase-3-results-in-dermatomyositis-setting-new-treatment-standard 2025-09-17T13:11:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brepocitinib-achieves-first-ever-positive-phase-3-results-in-dermatomyositis-setting-new-treatment-standard 2025-09-17T13:11:34+00:00 hourly 0.9 https://trial.medpath.com/news/uk-secures-zero-tariff-us-deal-and-increases-medicine-investment-to-accelerate-patient-access-to-breakthrough-treatments 2025-09-17T13:10:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-secures-zero-tariff-us-deal-and-increases-medicine-investment-to-accelerate-patient-access-to-breakthrough-treatments 2025-09-17T13:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/amber-implants-receives-fda-510-k-clearance-for-vcfix-spinal-system-to-treat-vertebral-compression-fractures 2025-09-17T13:09:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amber-implants-receives-fda-510-k-clearance-for-vcfix-spinal-system-to-treat-vertebral-compression-fractures 2025-09-17T13:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/microbiotica-completes-recruitment-for-phase-1b-trial-of-microbiome-therapy-mb097-in-treatment-resistant-melanoma 2025-09-17T13:09:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microbiotica-completes-recruitment-for-phase-1b-trial-of-microbiome-therapy-mb097-in-treatment-resistant-melanoma 2025-09-17T13:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-saphnelo-subcutaneous-formulation-meets-primary-endpoint-in-phase-iii-lupus-trial 2025-09-17T13:09:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-saphnelo-subcutaneous-formulation-meets-primary-endpoint-in-phase-iii-lupus-trial 2025-09-17T13:09:47+00:00 hourly 0.9 https://trial.medpath.com/news/uhnm-becomes-first-uk-site-to-recruit-patient-for-biontech-s-phase-3-small-cell-lung-cancer-trial 2025-09-17T13:09:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uhnm-becomes-first-uk-site-to-recruit-patient-for-biontech-s-phase-3-small-cell-lung-cancer-trial 2025-09-17T13:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/ernexa-therapeutics-to-present-breakthrough-erna-101-cell-therapy-data-at-aacr-ovarian-cancer-conference 2025-09-17T12:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ernexa-therapeutics-to-present-breakthrough-erna-101-cell-therapy-data-at-aacr-ovarian-cancer-conference 2025-09-17T12:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/innate-pharma-advances-key-pipeline-assets-while-implementing-strategic-restructuring 2025-09-17T09:11:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innate-pharma-advances-key-pipeline-assets-while-implementing-strategic-restructuring 2025-09-17T09:11:47+00:00 hourly 0.9 https://trial.medpath.com/news/vietnam-achieves-first-successful-car-t-cell-therapy-treatment-for-pediatric-acute-leukemia 2025-09-17T09:11:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vietnam-achieves-first-successful-car-t-cell-therapy-treatment-for-pediatric-acute-leukemia 2025-09-17T09:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-licenses-long-acting-monoclonal-antibody-tnx-4800-for-seasonal-lyme-disease-prevention 2025-09-17T09:11:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-licenses-long-acting-monoclonal-antibody-tnx-4800-for-seasonal-lyme-disease-prevention 2025-09-17T09:11:04+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-s-povorcitinib-shows-sustained-efficacy-in-phase-3-hidradenitis-suppurativa-trials-through-24-weeks 2025-09-17T09:10:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-s-povorcitinib-shows-sustained-efficacy-in-phase-3-hidradenitis-suppurativa-trials-through-24-weeks 2025-09-17T09:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/piramal-pharma-solutions-enhances-manufacturing-capabilities-with-advanced-bilayer-tablet-press-technology 2025-09-17T09:10:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/piramal-pharma-solutions-enhances-manufacturing-capabilities-with-advanced-bilayer-tablet-press-technology 2025-09-17T09:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-letters-to-eli-lilly-novo-nordisk-and-hims-over-misleading-weight-loss-drug-advertising 2025-09-17T09:09:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-warning-letters-to-eli-lilly-novo-nordisk-and-hims-over-misleading-weight-loss-drug-advertising 2025-09-17T09:09:11+00:00 hourly 0.9 https://trial.medpath.com/news/co-diagnostics-forms-joint-venture-with-saudi-arabian-partner-to-manufacture-pcr-diagnostics-platform 2025-09-17T09:08:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/co-diagnostics-forms-joint-venture-with-saudi-arabian-partner-to-manufacture-pcr-diagnostics-platform 2025-09-17T09:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/scienture-s-arbli-becomes-first-fda-approved-ready-to-use-liquid-losartan-securing-major-market-access 2025-09-17T05:14:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scienture-s-arbli-becomes-first-fda-approved-ready-to-use-liquid-losartan-securing-major-market-access 2025-09-17T05:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/hightide-therapeutics-htd1801-achieves-primary-endpoint-in-phase-3-type-2-diabetes-trial 2025-09-17T05:11:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hightide-therapeutics-htd1801-achieves-primary-endpoint-in-phase-3-type-2-diabetes-trial 2025-09-17T05:11:25+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-s-tau-antibody-etalanetug-receives-fda-fast-track-designation-for-alzheimer-s-disease 2025-09-17T05:09:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-s-tau-antibody-etalanetug-receives-fda-fast-track-designation-for-alzheimer-s-disease 2025-09-17T05:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/cytokinetics-raises-650-million-through-convertible-notes-to-fund-aficamten-commercial-launch 2025-09-17T01:15:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytokinetics-raises-650-million-through-convertible-notes-to-fund-aficamten-commercial-launch 2025-09-17T01:15:09+00:00 hourly 0.9 https://trial.medpath.com/news/auravax-secures-gates-foundation-grant-for-nanosting-001-influenza-challenge-study 2025-09-17T01:13:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/auravax-secures-gates-foundation-grant-for-nanosting-001-influenza-challenge-study 2025-09-17T01:13:26+00:00 hourly 0.9 https://trial.medpath.com/news/polypid-passes-fourth-consecutive-gmp-inspection-advances-d-plex100-toward-2026-nda-submission 2025-09-17T01:13:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polypid-passes-fourth-consecutive-gmp-inspection-advances-d-plex100-toward-2026-nda-submission 2025-09-17T01:13:21+00:00 hourly 0.9 https://trial.medpath.com/news/nxera-pharma-advances-novel-ep4-antagonist-htl0039732-to-phase-2a-trial-for-advanced-solid-tumors 2025-09-17T01:12:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nxera-pharma-advances-novel-ep4-antagonist-htl0039732-to-phase-2a-trial-for-advanced-solid-tumors 2025-09-17T01:12:58+00:00 hourly 0.9 https://trial.medpath.com/news/british-columbia-opens-first-phase-1-clinical-trials-unit-for-non-oncology-treatments 2025-09-17T01:12:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/british-columbia-opens-first-phase-1-clinical-trials-unit-for-non-oncology-treatments 2025-09-17T01:12:16+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-biosciences-advances-osavampator-to-phase-3-following-positive-depression-trial-results 2025-09-17T01:12:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-biosciences-advances-osavampator-to-phase-3-following-positive-depression-trial-results 2025-09-17T01:12:08+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-commits-30-billion-u-s-investment-to-advance-respiratory-and-cancer-medicine-manufacturing 2025-09-17T01:09:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-commits-30-billion-u-s-investment-to-advance-respiratory-and-cancer-medicine-manufacturing 2025-09-17T01:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/ir-med-s-pressuresafe-technology-advances-through-clinical-trials-targeting-26-8b-pressure-injury-market 2025-09-16T21:19:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ir-med-s-pressuresafe-technology-advances-through-clinical-trials-targeting-26-8b-pressure-injury-market 2025-09-16T21:19:59+00:00 hourly 0.9 https://trial.medpath.com/news/utr-therapeutics-publishes-preclinical-data-for-first-in-class-c-myc-rna-therapeutic-utrxm1-18 2025-09-16T21:18:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/utr-therapeutics-publishes-preclinical-data-for-first-in-class-c-myc-rna-therapeutic-utrxm1-18 2025-09-16T21:18:56+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-trial-confirms-shunt-surgery-benefits-for-older-adults-with-hydrocephalus 2025-09-16T21:15:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-trial-confirms-shunt-surgery-benefits-for-older-adults-with-hydrocephalus 2025-09-16T21:15:42+00:00 hourly 0.9 https://trial.medpath.com/news/blood-tests-show-promise-for-early-als-detection-years-before-symptoms-appear 2025-09-16T21:15:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-tests-show-promise-for-early-als-detection-years-before-symptoms-appear 2025-09-16T21:15:06+00:00 hourly 0.9 https://trial.medpath.com/news/yokogawa-and-repligen-partner-to-advance-real-time-bioprocess-monitoring-technology 2025-09-16T21:14:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yokogawa-and-repligen-partner-to-advance-real-time-bioprocess-monitoring-technology 2025-09-16T21:14:59+00:00 hourly 0.9 https://trial.medpath.com/news/roche-integrates-ai-enabled-accu-chek-smartguide-cgm-with-mysugr-app-following-ce-mark-approval 2025-09-16T21:13:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-integrates-ai-enabled-accu-chek-smartguide-cgm-with-mysugr-app-following-ce-mark-approval 2025-09-16T21:13:36+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-first-drug-patent-term-extensions-marking-new-era-for-pharmaceutical-ip-protection 2025-09-16T21:11:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-first-drug-patent-term-extensions-marking-new-era-for-pharmaceutical-ip-protection 2025-09-16T21:11:31+00:00 hourly 0.9 https://trial.medpath.com/news/gout-drug-pipeline-expands-with-25-novel-therapies-as-companies-target-unmet-medical-needs 2025-09-16T21:11:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gout-drug-pipeline-expands-with-25-novel-therapies-as-companies-target-unmet-medical-needs 2025-09-16T21:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/cantoni-therapeutics-secures-funding-to-advance-novel-nnmt-inhibitor-for-obesity-treatment 2025-09-16T17:20:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cantoni-therapeutics-secures-funding-to-advance-novel-nnmt-inhibitor-for-obesity-treatment 2025-09-16T17:20:52+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-divests-historic-china-joint-venture-stake-to-focus-on-innovation 2025-09-16T17:16:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-divests-historic-china-joint-venture-stake-to-focus-on-innovation 2025-09-16T17:16:51+00:00 hourly 0.9 https://trial.medpath.com/news/autolus-therapeutics-reports-promising-safety-profile-for-car-t-therapy-in-severe-lupus-patients 2025-09-16T17:16:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autolus-therapeutics-reports-promising-safety-profile-for-car-t-therapy-in-severe-lupus-patients 2025-09-16T17:16:18+00:00 hourly 0.9 https://trial.medpath.com/news/prt120-peanut-oral-immunotherapy-demonstrates-durable-3-year-remission-in-phase-2b-study 2025-09-16T17:15:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prt120-peanut-oral-immunotherapy-demonstrates-durable-3-year-remission-in-phase-2b-study 2025-09-16T17:15:47+00:00 hourly 0.9 https://trial.medpath.com/news/gaiaso-appoints-dr-tracey-brown-as-ceo-to-advance-precision-radiopharmaceuticals-for-women-s-cancers 2025-09-16T17:15:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gaiaso-appoints-dr-tracey-brown-as-ceo-to-advance-precision-radiopharmaceuticals-for-women-s-cancers 2025-09-16T17:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/enveric-biosciences-advances-eb-003-depression-treatment-directly-to-ind-submission-following-fda-guidance 2025-09-16T17:14:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enveric-biosciences-advances-eb-003-depression-treatment-directly-to-ind-submission-following-fda-guidance 2025-09-16T17:14:19+00:00 hourly 0.9 https://trial.medpath.com/news/ocugen-shares-surge-16-5-following-exclusive-korean-licensing-deal-for-ocu400-gene-therapy 2025-09-16T17:14:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocugen-shares-surge-16-5-following-exclusive-korean-licensing-deal-for-ocu400-gene-therapy 2025-09-16T17:14:13+00:00 hourly 0.9 https://trial.medpath.com/news/berlin-center-for-gene-and-cell-therapies-breaks-ground-creating-european-hub-for-advanced-therapeutics 2025-09-16T17:14:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/berlin-center-for-gene-and-cell-therapies-breaks-ground-creating-european-hub-for-advanced-therapeutics 2025-09-16T17:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/adaptimmune-s-tecelra-marks-first-engineered-cell-therapy-approval-for-solid-tumors-in-synovial-sarcoma 2025-09-16T17:13:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adaptimmune-s-tecelra-marks-first-engineered-cell-therapy-approval-for-solid-tumors-in-synovial-sarcoma 2025-09-16T17:13:56+00:00 hourly 0.9 https://trial.medpath.com/news/allrock-bio-secures-50-million-series-a-to-advance-first-in-class-pan-rock-inhibitor-for-pulmonary-hypertension 2025-09-16T17:13:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allrock-bio-secures-50-million-series-a-to-advance-first-in-class-pan-rock-inhibitor-for-pulmonary-hypertension 2025-09-16T17:13:54+00:00 hourly 0.9 https://trial.medpath.com/news/aptevo-s-mipletamig-achieves-100-remission-rate-in-phase-1b-2-aml-trial 2025-09-16T17:11:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptevo-s-mipletamig-achieves-100-remission-rate-in-phase-1b-2-aml-trial 2025-09-16T17:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/dualitas-therapeutics-emerges-from-stealth-with-65m-series-a-to-advance-bispecific-antibody-pipeline 2025-09-16T17:11:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dualitas-therapeutics-emerges-from-stealth-with-65m-series-a-to-advance-bispecific-antibody-pipeline 2025-09-16T17:11:12+00:00 hourly 0.9 https://trial.medpath.com/news/nuclidium-s-copper-based-pet-tracer-shows-promise-in-phase-i-ii-trial-for-neuroendocrine-tumor-detection 2025-09-16T17:10:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuclidium-s-copper-based-pet-tracer-shows-promise-in-phase-i-ii-trial-for-neuroendocrine-tumor-detection 2025-09-16T17:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/areteia-s-dexpramipexole-achieves-primary-endpoint-in-phase-iii-eosinophilic-asthma-trial 2025-09-16T17:10:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/areteia-s-dexpramipexole-achieves-primary-endpoint-in-phase-iii-eosinophilic-asthma-trial 2025-09-16T17:10:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-crb-701-adc-for-recurrent-head-and-neck-cancer 2025-09-16T17:10:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-crb-701-adc-for-recurrent-head-and-neck-cancer 2025-09-16T17:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/patensee-receives-fda-breakthrough-device-designation-for-ai-driven-hemodialysis-monitoring-system 2025-09-16T17:10:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patensee-receives-fda-breakthrough-device-designation-for-ai-driven-hemodialysis-monitoring-system 2025-09-16T17:10:20+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-commits-5-billion-to-virginia-manufacturing-facility-for-bioconjugate-and-adc-production 2025-09-16T17:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-commits-5-billion-to-virginia-manufacturing-facility-for-bioconjugate-and-adc-production 2025-09-16T17:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-launches-next-generation-acid-blocker-tegoprazan-in-india-following-phase-iii-success 2025-09-16T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-reddy-s-launches-next-generation-acid-blocker-tegoprazan-in-india-following-phase-iii-success 2025-09-16T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/metis-techbio-launches-ai-powered-nanoforge-platform-to-transform-drug-delivery 2025-09-16T17:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metis-techbio-launches-ai-powered-nanoforge-platform-to-transform-drug-delivery 2025-09-16T17:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/cook-myosite-advances-phase-iii-cell-therapy-trial-for-chronic-fecal-incontinence-in-women 2025-09-16T13:14:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cook-myosite-advances-phase-iii-cell-therapy-trial-for-chronic-fecal-incontinence-in-women 2025-09-16T13:14:02+00:00 hourly 0.9 https://trial.medpath.com/news/metabolic-surgery-demonstrates-superior-long-term-outcomes-over-glp-1-receptor-agonists-in-diabetes-and-obesity 2025-09-16T13:13:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metabolic-surgery-demonstrates-superior-long-term-outcomes-over-glp-1-receptor-agonists-in-diabetes-and-obesity 2025-09-16T13:13:34+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-durvalumab-for-limited-stage-small-cell-lung-cancer-first-treatment-advance-in-over-30-years 2025-09-16T13:12:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-approves-durvalumab-for-limited-stage-small-cell-lung-cancer-first-treatment-advance-in-over-30-years 2025-09-16T13:12:41+00:00 hourly 0.9 https://trial.medpath.com/news/fluoguide-receives-fda-alignment-for-fg001-intraoperative-imaging-agent-in-high-grade-glioma 2025-09-16T13:12:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fluoguide-receives-fda-alignment-for-fg001-intraoperative-imaging-agent-in-high-grade-glioma 2025-09-16T13:12:31+00:00 hourly 0.9 https://trial.medpath.com/news/aprecia-partners-with-apprentice-io-to-scale-ai-powered-3d-pharmaceutical-manufacturing 2025-09-16T13:10:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aprecia-partners-with-apprentice-io-to-scale-ai-powered-3d-pharmaceutical-manufacturing 2025-09-16T13:10:26+00:00 hourly 0.9 https://trial.medpath.com/news/zyvet-launches-first-fda-approved-generic-phenylpropanolamine-for-canine-urinary-incontinence 2025-09-16T13:10:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zyvet-launches-first-fda-approved-generic-phenylpropanolamine-for-canine-urinary-incontinence 2025-09-16T13:10:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-medical-device-for-asherman-syndrome-addressing-major-cause-of-female-infertility 2025-09-16T13:09:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-medical-device-for-asherman-syndrome-addressing-major-cause-of-female-infertility 2025-09-16T13:09:53+00:00 hourly 0.9 https://trial.medpath.com/news/tenax-therapeutics-secures-european-patent-protection-for-levosimendan-in-ph-hfpef-through-2040 2025-09-16T13:09:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenax-therapeutics-secures-european-patent-protection-for-levosimendan-in-ph-hfpef-through-2040 2025-09-16T13:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/aicuris-reports-positive-phase-2-results-for-pritelivir-in-refractory-hsv-infections-and-favorable-phase-1-safety-data-for-aic468 2025-09-16T09:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aicuris-reports-positive-phase-2-results-for-pritelivir-in-refractory-hsv-infections-and-favorable-phase-1-safety-data-for-aic468 2025-09-16T09:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/henlius-biotech-in-advanced-licensing-talks-with-j-j-and-roche-for-experimental-cancer-drug 2025-09-16T09:10:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/henlius-biotech-in-advanced-licensing-talks-with-j-j-and-roche-for-experimental-cancer-drug 2025-09-16T09:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/ferroptosis-inducing-drug-auranofin-shows-promise-in-combination-with-chemotherapy-for-resistant-neuroblastoma 2025-09-16T09:09:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ferroptosis-inducing-drug-auranofin-shows-promise-in-combination-with-chemotherapy-for-resistant-neuroblastoma 2025-09-16T09:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-510-k-clearance-for-apollo-tms-device-to-treat-major-depressive-disorder-in-adolescents 2025-09-16T09:09:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-510-k-clearance-for-apollo-tms-device-to-treat-major-depressive-disorder-in-adolescents 2025-09-16T09:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/race-oncology-discovers-novel-bisantrene-photoisomers-files-patent-applications-for-20-year-protection 2025-09-16T09:09:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/race-oncology-discovers-novel-bisantrene-photoisomers-files-patent-applications-for-20-year-protection 2025-09-16T09:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-vyjuvek-label-for-home-use-and-all-ages-boosting-krystal-biotech-s-market-potential 2025-09-16T09:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-vyjuvek-label-for-home-use-and-all-ages-boosting-krystal-biotech-s-market-potential 2025-09-16T09:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/anacardio-completes-phase-2a-enrollment-for-heart-failure-drug-candidate-ac01 2025-09-16T09:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anacardio-completes-phase-2a-enrollment-for-heart-failure-drug-candidate-ac01 2025-09-16T09:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/alpha-modus-expands-patent-enforcement-campaign-with-lawsuit-against-indian-ai-retail-company-allerin-tech 2025-09-16T05:10:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alpha-modus-expands-patent-enforcement-campaign-with-lawsuit-against-indian-ai-retail-company-allerin-tech 2025-09-16T05:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/drug-hunter-secures-seed-investment-to-expand-knowledge-platform-for-pharmaceutical-r-d 2025-09-16T05:09:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drug-hunter-secures-seed-investment-to-expand-knowledge-platform-for-pharmaceutical-r-d 2025-09-16T05:09:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-set-to-review-five-key-pediatric-and-adult-therapies-in-q4-2025 2025-09-16T05:09:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-set-to-review-five-key-pediatric-and-adult-therapies-in-q4-2025 2025-09-16T05:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/race-oncology-secures-breakthrough-patent-protection-for-purified-bisantrene-cancer-drug 2025-09-16T05:09:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/race-oncology-secures-breakthrough-patent-protection-for-purified-bisantrene-cancer-drug 2025-09-16T05:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/crism-therapeutics-advances-toward-phase-2-glioblastoma-trial-despite-widening-losses 2025-09-16T05:08:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crism-therapeutics-advances-toward-phase-2-glioblastoma-trial-despite-widening-losses 2025-09-16T05:08:59+00:00 hourly 0.9 https://trial.medpath.com/news/turn-therapeutics-prepares-for-nasdaq-debut-with-focus-on-dermatology-and-infectious-disease-programs 2025-09-16T01:18:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/turn-therapeutics-prepares-for-nasdaq-debut-with-focus-on-dermatology-and-infectious-disease-programs 2025-09-16T01:18:17+00:00 hourly 0.9 https://trial.medpath.com/news/altimmune-appoints-linda-richardson-as-chief-commercial-officer-ahead-of-pemvidutide-phase-3-mash-trial 2025-09-16T01:17:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altimmune-appoints-linda-richardson-as-chief-commercial-officer-ahead-of-pemvidutide-phase-3-mash-trial 2025-09-16T01:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/nyxoah-files-patent-infringement-lawsuit-against-inspire-medical-systems-over-sleep-apnea-devices 2025-09-16T01:15:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyxoah-files-patent-infringement-lawsuit-against-inspire-medical-systems-over-sleep-apnea-devices 2025-09-16T01:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/indian-patent-office-revokes-novartis-vymada-patent-opening-door-for-generic-competition 2025-09-16T01:14:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-patent-office-revokes-novartis-vymada-patent-opening-door-for-generic-competition 2025-09-16T01:14:45+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-wegovy-shows-46-reduction-in-food-noise-and-improved-mental-health-in-real-world-survey 2025-09-16T01:14:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-wegovy-shows-46-reduction-in-food-noise-and-improved-mental-health-in-real-world-survey 2025-09-16T01:14:01+00:00 hourly 0.9 https://trial.medpath.com/news/mit-and-bidmc-teams-advance-novel-mrna-based-tuberculosis-vaccines-using-newly-identified-antigens 2025-09-16T01:13:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mit-and-bidmc-teams-advance-novel-mrna-based-tuberculosis-vaccines-using-newly-identified-antigens 2025-09-16T01:13:55+00:00 hourly 0.9 https://trial.medpath.com/news/cook-medical-and-siemens-healthineers-launch-radiation-free-interventional-mri-suite-for-real-time-minimally-invasive-procedures 2025-09-16T01:13:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cook-medical-and-siemens-healthineers-launch-radiation-free-interventional-mri-suite-for-real-time-minimally-invasive-procedures 2025-09-16T01:13:39+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-safety-analysis-reveals-new-adverse-events-for-fenfluramine-in-rare-epilepsy-syndromes 2025-09-15T21:13:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-safety-analysis-reveals-new-adverse-events-for-fenfluramine-in-rare-epilepsy-syndromes 2025-09-15T21:13:52+00:00 hourly 0.9 https://trial.medpath.com/news/atyr-pharma-s-efzofitimod-fails-phase-3-trial-for-pulmonary-sarcoidosis 2025-09-15T21:11:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atyr-pharma-s-efzofitimod-fails-phase-3-trial-for-pulmonary-sarcoidosis 2025-09-15T21:11:49+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-shows-glp-1-receptor-agonists-effective-for-pediatric-obesity-and-type-2-diabetes 2025-09-15T21:11:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meta-analysis-shows-glp-1-receptor-agonists-effective-for-pediatric-obesity-and-type-2-diabetes 2025-09-15T21:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/smith-nephew-s-regeneten-bioinductive-implant-receives-aaos-strong-recommendation-following-65-reduction-in-rotator-cuff-re-tear-rates 2025-09-15T21:11:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smith-nephew-s-regeneten-bioinductive-implant-receives-aaos-strong-recommendation-following-65-reduction-in-rotator-cuff-re-tear-rates 2025-09-15T21:11:18+00:00 hourly 0.9 https://trial.medpath.com/news/labconnect-and-omniscience-partner-to-launch-first-agentic-ai-platform-for-real-time-clinical-trial-lab-data-analysis 2025-09-15T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/labconnect-and-omniscience-partner-to-launch-first-agentic-ai-platform-for-real-time-clinical-trial-lab-data-analysis 2025-09-15T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/cms-finalizes-third-round-of-medicare-drug-price-negotiations-with-expanded-orphan-drug-exclusions 2025-09-15T21:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-finalizes-third-round-of-medicare-drug-price-negotiations-with-expanded-orphan-drug-exclusions 2025-09-15T21:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/parexel-forms-strategic-ai-partnerships-to-accelerate-drug-development-and-clinical-trial-efficiency 2025-09-15T20:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parexel-forms-strategic-ai-partnerships-to-accelerate-drug-development-and-clinical-trial-efficiency 2025-09-15T20:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/proteonic-launches-2g-unic-transposon-platform-for-enhanced-biologics-production 2025-09-15T17:31:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proteonic-launches-2g-unic-transposon-platform-for-enhanced-biologics-production 2025-09-15T17:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/federal-courts-uphold-state-340b-protection-laws-against-pharmaceutical-challenges 2025-09-15T17:30:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-courts-uphold-state-340b-protection-laws-against-pharmaceutical-challenges 2025-09-15T17:30:24+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-challenges-rhode-island-s-340b-drug-pricing-law-in-federal-court 2025-09-15T17:28:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-challenges-rhode-island-s-340b-drug-pricing-law-in-federal-court 2025-09-15T17:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/serine-free-diet-shows-promise-in-slowing-glioblastoma-growth-and-enhancing-treatment-response 2025-09-15T17:27:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/serine-free-diet-shows-promise-in-slowing-glioblastoma-growth-and-enhancing-treatment-response 2025-09-15T17:27:48+00:00 hourly 0.9 https://trial.medpath.com/news/mycenax-biotech-and-spera-pharma-form-strategic-alliance-to-enhance-adc-manufacturing-capabilities 2025-09-15T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mycenax-biotech-and-spera-pharma-form-strategic-alliance-to-enhance-adc-manufacturing-capabilities 2025-09-15T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/humacyte-s-symvess-demonstrates-92-patency-rate-in-hospital-acquired-vascular-complications-study 2025-09-15T17:25:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/humacyte-s-symvess-demonstrates-92-patency-rate-in-hospital-acquired-vascular-complications-study 2025-09-15T17:25:05+00:00 hourly 0.9 https://trial.medpath.com/news/lindis-blood-care-s-catuvab-device-achieves-100-tumor-cell-removal-in-pivotal-cancer-surgery-study 2025-09-15T17:23:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lindis-blood-care-s-catuvab-device-achieves-100-tumor-cell-removal-in-pivotal-cancer-surgery-study 2025-09-15T17:23:51+00:00 hourly 0.9 https://trial.medpath.com/news/sohm-secures-south-korean-patent-for-crispr-based-gene-editing-platform-targeting-car-t-therapy-development 2025-09-15T17:23:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sohm-secures-south-korean-patent-for-crispr-based-gene-editing-platform-targeting-car-t-therapy-development 2025-09-15T17:23:29+00:00 hourly 0.9 https://trial.medpath.com/news/gyala-therapeutics-advances-first-in-class-cd84-targeting-car-t-therapy-with-eur3-million-funding-for-aml-and-t-all-treatment 2025-09-15T17:22:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gyala-therapeutics-advances-first-in-class-cd84-targeting-car-t-therapy-with-eur3-million-funding-for-aml-and-t-all-treatment 2025-09-15T17:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/biparametric-mri-proves-noninferior-to-standard-multiparametric-mri-for-prostate-cancer-detection-in-prime-trial 2025-09-15T17:22:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biparametric-mri-proves-noninferior-to-standard-multiparametric-mri-for-prostate-cancer-detection-in-prime-trial 2025-09-15T17:22:29+00:00 hourly 0.9 https://trial.medpath.com/news/avalyn-pharma-unveils-aura-ipf-phase-2-trial-design-for-inhaled-nintedanib-at-ers-congress-2025 2025-09-15T17:22:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avalyn-pharma-unveils-aura-ipf-phase-2-trial-design-for-inhaled-nintedanib-at-ers-congress-2025 2025-09-15T17:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/labcorp-completes-225-million-acquisition-of-bioreference-health-s-oncology-testing-assets 2025-09-15T17:21:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/labcorp-completes-225-million-acquisition-of-bioreference-health-s-oncology-testing-assets 2025-09-15T17:21:56+00:00 hourly 0.9 https://trial.medpath.com/news/made-scientific-partners-with-basilard-biotech-to-advance-nanomechanical-gene-delivery-platform-for-cell-therapies 2025-09-15T17:21:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/made-scientific-partners-with-basilard-biotech-to-advance-nanomechanical-gene-delivery-platform-for-cell-therapies 2025-09-15T17:21:25+00:00 hourly 0.9 https://trial.medpath.com/news/conceivable-life-sciences-raises-50-million-series-a-to-commercialize-ai-powered-automated-ivf-laboratory 2025-09-15T17:20:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/conceivable-life-sciences-raises-50-million-series-a-to-commercialize-ai-powered-automated-ivf-laboratory 2025-09-15T17:20:39+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-vraylar-achieves-full-provincial-coverage-in-canada-with-alberta-reimbursement-approval 2025-09-15T17:20:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-vraylar-achieves-full-provincial-coverage-in-canada-with-alberta-reimbursement-approval 2025-09-15T17:20:29+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-achieves-commercial-manufacturing-milestone-for-rdeb-cell-therapy-cordstromtm 2025-09-15T17:18:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmune-bio-achieves-commercial-manufacturing-milestone-for-rdeb-cell-therapy-cordstromtm 2025-09-15T17:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-presents-phase-3-data-for-seltorexant-in-major-depressive-disorder-at-2025-psych-congress 2025-09-15T17:18:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-presents-phase-3-data-for-seltorexant-in-major-depressive-disorder-at-2025-psych-congress 2025-09-15T17:18:07+00:00 hourly 0.9 https://trial.medpath.com/news/emergent-biosolutions-secures-17-million-barda-contract-for-smallpox-antiviral-tembexa-oral-suspension 2025-09-15T17:18:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emergent-biosolutions-secures-17-million-barda-contract-for-smallpox-antiviral-tembexa-oral-suspension 2025-09-15T17:18:01+00:00 hourly 0.9 https://trial.medpath.com/news/fire-trial-shows-supraflex-cruz-stent-reduces-cardiovascular-events-in-elderly-heart-attack-patients 2025-09-15T17:17:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fire-trial-shows-supraflex-cruz-stent-reduces-cardiovascular-events-in-elderly-heart-attack-patients 2025-09-15T17:17:25+00:00 hourly 0.9 https://trial.medpath.com/news/cadrenal-therapeutics-acquires-exithera-s-factor-xia-inhibitor-portfolio-in-15m-deal 2025-09-15T17:16:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cadrenal-therapeutics-acquires-exithera-s-factor-xia-inhibitor-portfolio-in-15m-deal 2025-09-15T17:16:56+00:00 hourly 0.9 https://trial.medpath.com/news/rona-therapeutics-files-ind-for-rn3161-novel-sirna-targeting-inhbe-for-obesity-treatment 2025-09-15T17:15:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rona-therapeutics-files-ind-for-rn3161-novel-sirna-targeting-inhbe-for-obesity-treatment 2025-09-15T17:15:55+00:00 hourly 0.9 https://trial.medpath.com/news/protagonist-to-present-phase-2b-icotrokinra-data-for-ulcerative-colitis-at-european-gastroenterology-week 2025-09-15T17:15:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protagonist-to-present-phase-2b-icotrokinra-data-for-ulcerative-colitis-at-european-gastroenterology-week 2025-09-15T17:15:11+00:00 hourly 0.9 https://trial.medpath.com/news/renalytix-partners-with-tempus-ai-to-expand-access-to-fda-approved-kidney-disease-risk-test 2025-09-15T17:14:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renalytix-partners-with-tempus-ai-to-expand-access-to-fda-approved-kidney-disease-risk-test 2025-09-15T17:14:57+00:00 hourly 0.9 https://trial.medpath.com/news/argo-biopharma-advances-sirna-therapy-bw-40202-to-phase-ii-trial-for-paroxysmal-nocturnal-hemoglobinuria 2025-09-15T17:14:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/argo-biopharma-advances-sirna-therapy-bw-40202-to-phase-ii-trial-for-paroxysmal-nocturnal-hemoglobinuria 2025-09-15T17:14:51+00:00 hourly 0.9 https://trial.medpath.com/news/biocartis-receives-fda-approval-for-first-fully-automated-companion-diagnostic-test-for-colorectal-cancer 2025-09-15T17:13:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocartis-receives-fda-approval-for-first-fully-automated-companion-diagnostic-test-for-colorectal-cancer 2025-09-15T17:13:58+00:00 hourly 0.9 https://trial.medpath.com/news/modular-medical-receives-irb-approval-for-pivot-insulin-delivery-system-feasibility-study 2025-09-15T17:13:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modular-medical-receives-irb-approval-for-pivot-insulin-delivery-system-feasibility-study 2025-09-15T17:13:56+00:00 hourly 0.9 https://trial.medpath.com/news/biostar-pharma-initiates-two-phase-ii-iii-trials-for-utidelone-capsule-in-gastric-and-ovarian-cancers 2025-09-15T17:12:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biostar-pharma-initiates-two-phase-ii-iii-trials-for-utidelone-capsule-in-gastric-and-ovarian-cancers 2025-09-15T17:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-s-glac-biotech-receives-fda-gras-approval-for-probiotic-strain-cp-9-expanding-infant-nutrition-portfolio 2025-09-15T17:11:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiwan-s-glac-biotech-receives-fda-gras-approval-for-probiotic-strain-cp-9-expanding-infant-nutrition-portfolio 2025-09-15T17:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/sagent-pharmaceuticals-enters-8-6-billion-ophthalmic-market-with-travoprost-launch 2025-09-15T17:11:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sagent-pharmaceuticals-enters-8-6-billion-ophthalmic-market-with-travoprost-launch 2025-09-15T17:11:39+00:00 hourly 0.9 https://trial.medpath.com/news/proofpilot-acquires-lokavant-to-enhance-clinical-trial-performance-with-ai-powered-predictive-analytics 2025-09-15T17:11:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proofpilot-acquires-lokavant-to-enhance-clinical-trial-performance-with-ai-powered-predictive-analytics 2025-09-15T17:11:32+00:00 hourly 0.9 https://trial.medpath.com/news/worldwide-clinical-trials-appoints-alistair-macdonald-as-new-ceo-following-peter-benton-s-retirement 2025-09-15T17:11:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/worldwide-clinical-trials-appoints-alistair-macdonald-as-new-ceo-following-peter-benton-s-retirement 2025-09-15T17:11:30+00:00 hourly 0.9 https://trial.medpath.com/news/uci-mind-receives-18-million-nih-grant-to-establish-first-trial-ready-cohort-for-late-dementia 2025-09-15T17:11:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uci-mind-receives-18-million-nih-grant-to-establish-first-trial-ready-cohort-for-late-dementia 2025-09-15T17:11:14+00:00 hourly 0.9 https://trial.medpath.com/news/icecure-medical-advances-cryoablation-technology-with-patent-approval-and-regulatory-clearance-for-xsense-system 2025-09-15T17:10:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icecure-medical-advances-cryoablation-technology-with-patent-approval-and-regulatory-clearance-for-xsense-system 2025-09-15T17:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/b-braun-completes-full-acquisition-of-true-digital-surgery-to-advance-digital-microsurgery-technology 2025-09-15T14:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/b-braun-completes-full-acquisition-of-true-digital-surgery-to-advance-digital-microsurgery-technology 2025-09-15T14:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-launches-pivotal-trial-testing-personalized-pacing-therapy-for-heart-failure-patients 2025-09-15T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-launches-pivotal-trial-testing-personalized-pacing-therapy-for-heart-failure-patients 2025-09-15T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ondine-biomedical-s-steriwave-technology-shows-99-9-efficacy-against-drug-resistant-c-auris-as-european-cases-surge-67 2025-09-15T13:13:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ondine-biomedical-s-steriwave-technology-shows-99-9-efficacy-against-drug-resistant-c-auris-as-european-cases-surge-67 2025-09-15T13:13:45+00:00 hourly 0.9 https://trial.medpath.com/news/catalym-strengthens-leadership-team-to-advance-visugromab-through-late-stage-development 2025-09-15T13:13:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catalym-strengthens-leadership-team-to-advance-visugromab-through-late-stage-development 2025-09-15T13:13:01+00:00 hourly 0.9 https://trial.medpath.com/news/kodiak-sciences-ksi-101-demonstrates-62-vision-improvement-in-phase-1b-mesi-trial 2025-09-15T13:12:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kodiak-sciences-ksi-101-demonstrates-62-vision-improvement-in-phase-1b-mesi-trial 2025-09-15T13:12:55+00:00 hourly 0.9 https://trial.medpath.com/news/genflow-biosciences-signs-cdas-with-animal-health-companies-to-advance-sirt6-gene-therapy-platform 2025-09-15T13:12:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genflow-biosciences-signs-cdas-with-animal-health-companies-to-advance-sirt6-gene-therapy-platform 2025-09-15T13:12:50+00:00 hourly 0.9 https://trial.medpath.com/news/ocugen-partners-with-kwangdong-for-ocu400-gene-therapy-in-korea-with-7-5m-upfront-deal 2025-09-15T13:12:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocugen-partners-with-kwangdong-for-ocu400-gene-therapy-in-korea-with-7-5m-upfront-deal 2025-09-15T13:12:07+00:00 hourly 0.9 https://trial.medpath.com/news/can-fite-reports-complete-resolution-of-esophageal-varices-in-decompensated-cirrhosis-patient-treated-with-namodenoson 2025-09-15T13:11:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/can-fite-reports-complete-resolution-of-esophageal-varices-in-decompensated-cirrhosis-patient-treated-with-namodenoson 2025-09-15T13:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/som-biotech-secures-european-orphan-drug-designation-for-huntington-s-disease-therapy-som3355 2025-09-15T13:11:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/som-biotech-secures-european-orphan-drug-designation-for-huntington-s-disease-therapy-som3355 2025-09-15T13:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/international-research-team-secures-800000-to-advance-first-potentially-regenerative-multiple-sclerosis-treatment 2025-09-15T13:11:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/international-research-team-secures-800000-to-advance-first-potentially-regenerative-multiple-sclerosis-treatment 2025-09-15T13:11:12+00:00 hourly 0.9 https://trial.medpath.com/news/curatis-advances-c-ptbe-01-toward-phase-iii-trial-following-positive-fda-meeting 2025-09-15T13:10:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curatis-advances-c-ptbe-01-toward-phase-iii-trial-following-positive-fda-meeting 2025-09-15T13:10:57+00:00 hourly 0.9 https://trial.medpath.com/news/dexcom-unveils-smart-basal-feature-and-presents-clinical-evidence-at-easd-2025 2025-09-15T13:10:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dexcom-unveils-smart-basal-feature-and-presents-clinical-evidence-at-easd-2025 2025-09-15T13:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/novocure-s-optune-lua-receives-japanese-approval-for-advanced-nsclc-treatment 2025-09-15T13:10:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novocure-s-optune-lua-receives-japanese-approval-for-advanced-nsclc-treatment 2025-09-15T13:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/avita-medical-secures-ce-mark-for-recell-go-expanding-burn-treatment-access-across-europe 2025-09-15T09:14:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avita-medical-secures-ce-mark-for-recell-go-expanding-burn-treatment-access-across-europe 2025-09-15T09:14:09+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-advances-australian-discovered-kat6-inhibitor-pf-07248144-to-phase-3-trial-for-hr-her2-metastatic-breast-cancer 2025-09-15T09:11:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-advances-australian-discovered-kat6-inhibitor-pf-07248144-to-phase-3-trial-for-hr-her2-metastatic-breast-cancer 2025-09-15T09:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/qlife-advances-two-home-diagnostic-tests-for-heart-failure-into-clinical-trials 2025-09-15T09:09:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qlife-advances-two-home-diagnostic-tests-for-heart-failure-into-clinical-trials 2025-09-15T09:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/seven-real-world-studies-demonstrate-nefecon-s-efficacy-in-iga-nephropathy-treatment-across-diverse-patient-populations 2025-09-15T06:08:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seven-real-world-studies-demonstrate-nefecon-s-efficacy-in-iga-nephropathy-treatment-across-diverse-patient-populations 2025-09-15T06:08:49+00:00 hourly 0.9 https://trial.medpath.com/news/everbridge-group-secures-exclusive-japanese-market-partnership-with-cosmotec-for-medical-device-commercialization 2025-09-15T06:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/everbridge-group-secures-exclusive-japanese-market-partnership-with-cosmotec-for-medical-device-commercialization 2025-09-15T06:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/phrontline-biopharma-initiates-phase-1-trial-for-tj101-dual-target-adc-in-solid-tumors 2025-09-15T04:09:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phrontline-biopharma-initiates-phase-1-trial-for-tj101-dual-target-adc-in-solid-tumors 2025-09-15T04:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/cleo-diagnostics-receives-positive-fda-feedback-for-ovarian-cancer-blood-test-advancing-toward-us-approval 2025-09-15T04:09:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleo-diagnostics-receives-positive-fda-feedback-for-ovarian-cancer-blood-test-advancing-toward-us-approval 2025-09-15T04:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/lion-tcr-receives-fda-ind-clearance-for-first-in-class-tcr-t-therapy-targeting-chronic-hepatitis-b 2025-09-15T04:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lion-tcr-receives-fda-ind-clearance-for-first-in-class-tcr-t-therapy-targeting-chronic-hepatitis-b 2025-09-15T04:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/agios-pharmaceuticals-faces-securities-fraud-investigation-following-fda-delay-of-pyrukynd-approval 2025-09-15T01:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agios-pharmaceuticals-faces-securities-fraud-investigation-following-fda-delay-of-pyrukynd-approval 2025-09-15T01:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/nurix-therapeutics-advances-bexobrutideg-phase-iii-program-and-expands-protein-degrader-pipeline 2025-09-14T21:14:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nurix-therapeutics-advances-bexobrutideg-phase-iii-program-and-expands-protein-degrader-pipeline 2025-09-14T21:14:05+00:00 hourly 0.9 https://trial.medpath.com/news/cocrystal-pharma-advances-antiviral-pipeline-with-13m-funding-cdi-988-enters-phase-1b-human-challenge-study 2025-09-14T17:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cocrystal-pharma-advances-antiviral-pipeline-with-13m-funding-cdi-988-enters-phase-1b-human-challenge-study 2025-09-14T17:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/monopar-s-alxn1840-shows-sustained-neurological-benefits-in-long-term-wilson-disease-study 2025-09-14T17:09:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monopar-s-alxn1840-shows-sustained-neurological-benefits-in-long-term-wilson-disease-study 2025-09-14T17:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-hiv-antibody-04-a06-neutralizes-98-5-of-viral-strains-in-preclinical-studies 2025-09-14T17:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-hiv-antibody-04-a06-neutralizes-98-5-of-viral-strains-in-preclinical-studies 2025-09-14T17:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/globe-biotech-secures-first-us-patent-for-bangladesh-with-single-dose-covid-19-mrna-vaccine 2025-09-14T13:09:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/globe-biotech-secures-first-us-patent-for-bangladesh-with-single-dose-covid-19-mrna-vaccine 2025-09-14T13:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharmaceuticals-receives-usfda-clearance-for-api-manufacturing-facilities-following-may-inspection 2025-09-14T13:08:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alembic-pharmaceuticals-receives-usfda-clearance-for-api-manufacturing-facilities-following-may-inspection 2025-09-14T13:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/indian-researchers-develop-cassava-starch-patches-for-oral-cancer-and-leukoplakia-treatment 2025-09-14T09:08:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-researchers-develop-cassava-starch-patches-for-oral-cancer-and-leukoplakia-treatment 2025-09-14T09:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-approves-phase-i-trial-for-jeevan-scientific-s-bevacizumab-biosimilar-in-india 2025-09-14T09:08:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-approves-phase-i-trial-for-jeevan-scientific-s-bevacizumab-biosimilar-in-india 2025-09-14T09:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-partners-with-asian-hospital-to-expand-access-to-rare-disease-treatments-in-philippines 2025-09-14T05:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-partners-with-asian-hospital-to-expand-access-to-rare-disease-treatments-in-philippines 2025-09-14T05:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/novocure-s-optune-lua-receives-fda-approval-for-metastatic-non-small-cell-lung-cancer-extending-survival-by-3-3-months 2025-09-14T05:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novocure-s-optune-lua-receives-fda-approval-for-metastatic-non-small-cell-lung-cancer-extending-survival-by-3-3-months 2025-09-14T05:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/indian-pharma-companies-leverage-fda-505-b-2-pathway-to-create-differentiated-generics-with-merck-support 2025-09-14T01:10:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-pharma-companies-leverage-fda-505-b-2-pathway-to-create-differentiated-generics-with-merck-support 2025-09-14T01:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/vietnam-and-russia-sign-major-biopharmaceutical-technology-transfer-agreement-for-advanced-drug-production 2025-09-14T01:10:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vietnam-and-russia-sign-major-biopharmaceutical-technology-transfer-agreement-for-advanced-drug-production 2025-09-14T01:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/lila-sciences-achieves-unicorn-status-with-235m-funding-for-ai-driven-drug-discovery-platform 2025-09-14T01:08:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lila-sciences-achieves-unicorn-status-with-235m-funding-for-ai-driven-drug-discovery-platform 2025-09-14T01:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-stock-deemed-undervalued-following-recent-fda-approval-and-market-decline 2025-09-14T01:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-stock-deemed-undervalued-following-recent-fda-approval-and-market-decline 2025-09-14T01:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-scientists-develop-revolutionary-bone-02-adhesive-that-heals-fractures-in-three-minutes 2025-09-13T21:08:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-scientists-develop-revolutionary-bone-02-adhesive-that-heals-fractures-in-three-minutes 2025-09-13T21:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-stock-deemed-undervalued-following-recent-fda-approval-despite-20-8-annual-gains 2025-09-13T17:10:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-stock-deemed-undervalued-following-recent-fda-approval-despite-20-8-annual-gains 2025-09-13T17:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/apollo-hospitals-invests-rs-573-crore-in-advanced-proton-therapy-oncology-center-in-gurugram 2025-09-13T17:10:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apollo-hospitals-invests-rs-573-crore-in-advanced-proton-therapy-oncology-center-in-gurugram 2025-09-13T17:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-draft-guidance-on-non-opioid-pain-therapies-could-accelerate-apitox-development-for-osteoarthritis 2025-09-13T17:08:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-draft-guidance-on-non-opioid-pain-therapies-could-accelerate-apitox-development-for-osteoarthritis 2025-09-13T17:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/verona-pharma-and-vertex-pharmaceuticals-show-divergent-valuation-patterns-following-recent-fda-approvals 2025-09-13T17:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verona-pharma-and-vertex-pharmaceuticals-show-divergent-valuation-patterns-following-recent-fda-approvals 2025-09-13T17:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/alligator-bioscience-presents-promising-preclinical-data-for-ator-4066-bispecific-antibody-at-cicon25 2025-09-13T13:09:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alligator-bioscience-presents-promising-preclinical-data-for-ator-4066-bispecific-antibody-at-cicon25 2025-09-13T13:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-lotus-study-shows-sustained-efficacy-of-daybue-in-rett-syndrome-patients-over-12-months 2025-09-13T13:09:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-lotus-study-shows-sustained-efficacy-of-daybue-in-rett-syndrome-patients-over-12-months 2025-09-13T13:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/mallinckrodt-wins-9-5m-patent-infringement-award-in-nitric-oxide-therapy-case 2025-09-13T10:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mallinckrodt-wins-9-5m-patent-infringement-award-in-nitric-oxide-therapy-case 2025-09-13T10:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/triastek-opens-world-s-largest-3d-printed-pharmaceutical-facility-in-china-targets-300-million-tablets-annually 2025-09-13T09:09:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triastek-opens-world-s-largest-3d-printed-pharmaceutical-facility-in-china-targets-300-million-tablets-annually 2025-09-13T09:09:47+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-analysis-reveals-cardiac-failure-risk-varies-significantly-among-breast-cancer-therapies 2025-09-13T09:09:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-analysis-reveals-cardiac-failure-risk-varies-significantly-among-breast-cancer-therapies 2025-09-13T09:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/fore-biotherapeutics-reports-durable-clinical-benefit-with-plixorafenib-in-braf-altered-thyroid-cancers 2025-09-13T05:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fore-biotherapeutics-reports-durable-clinical-benefit-with-plixorafenib-in-braf-altered-thyroid-cancers 2025-09-13T05:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/yoltech-therapeutics-secures-45-million-series-b-funding-to-advance-in-vivo-gene-editing-pipeline 2025-09-13T05:08:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yoltech-therapeutics-secures-45-million-series-b-funding-to-advance-in-vivo-gene-editing-pipeline 2025-09-13T05:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/musc-launches-clinical-trial-for-heart-safe-triple-negative-breast-cancer-treatment 2025-09-13T05:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/musc-launches-clinical-trial-for-heart-safe-triple-negative-breast-cancer-treatment 2025-09-13T05:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/novel-bispecific-antibody-combinations-show-promise-in-indolent-lymphoma-treatment 2025-09-13T02:10:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-bispecific-antibody-combinations-show-promise-in-indolent-lymphoma-treatment 2025-09-13T02:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/agios-mitapivat-receives-positive-chmp-opinion-for-thalassemia-treatment-in-europe 2025-09-13T01:10:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agios-mitapivat-receives-positive-chmp-opinion-for-thalassemia-treatment-in-europe 2025-09-13T01:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/uci-health-s-stopgap-ii-trial-advances-to-national-phase-for-advanced-gastric-cancer-treatment 2025-09-13T01:10:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uci-health-s-stopgap-ii-trial-advances-to-national-phase-for-advanced-gastric-cancer-treatment 2025-09-13T01:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/rybrevant-plus-lazcluze-combination-demonstrates-superior-overall-survival-in-first-line-egfr-mutated-nsclc 2025-09-13T01:10:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rybrevant-plus-lazcluze-combination-demonstrates-superior-overall-survival-in-first-line-egfr-mutated-nsclc 2025-09-13T01:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/uni-bio-science-group-partners-with-kexing-biopharm-to-expand-osteoporosis-treatment-bogutai-r-to-six-international-markets 2025-09-13T01:09:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uni-bio-science-group-partners-with-kexing-biopharm-to-expand-osteoporosis-treatment-bogutai-r-to-six-international-markets 2025-09-13T01:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/fermenta-biotech-secures-patent-for-plant-based-vitamin-d3-production-technology 2025-09-12T21:12:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fermenta-biotech-secures-patent-for-plant-based-vitamin-d3-production-technology 2025-09-12T21:12:02+00:00 hourly 0.9 https://trial.medpath.com/news/australian-court-denies-preliminary-injunction-against-sandoz-aflibercept-biosimilar-launch 2025-09-12T21:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-court-denies-preliminary-injunction-against-sandoz-aflibercept-biosimilar-launch 2025-09-12T21:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/nevian-lifescience-launches-first-locally-manufactured-novartis-medicine-following-bangladesh-acquisition 2025-09-12T21:10:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nevian-lifescience-launches-first-locally-manufactured-novartis-medicine-following-bangladesh-acquisition 2025-09-12T21:10:02+00:00 hourly 0.9 https://trial.medpath.com/news/oncotelic-therapeutics-reports-progress-across-six-late-stage-drug-programs-in-oncology-and-rare-diseases 2025-09-12T21:09:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncotelic-therapeutics-reports-progress-across-six-late-stage-drug-programs-in-oncology-and-rare-diseases 2025-09-12T21:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/novel-pcsk9-inhibitor-recaticimab-shows-54-ldl-cholesterol-reduction-in-phase-3-trial-for-familial-hypercholesterolemia 2025-09-12T21:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-pcsk9-inhibitor-recaticimab-shows-54-ldl-cholesterol-reduction-in-phase-3-trial-for-familial-hypercholesterolemia 2025-09-12T21:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/zoetis-receives-eu-regulatory-nod-for-first-long-acting-feline-osteoarthritis-pain-treatment 2025-09-12T21:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zoetis-receives-eu-regulatory-nod-for-first-long-acting-feline-osteoarthritis-pain-treatment 2025-09-12T21:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-plans-to-present-data-linking-covid-19-vaccines-to-25-pediatric-deaths-at-cdc-advisory-meeting 2025-09-12T21:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-plans-to-present-data-linking-covid-19-vaccines-to-25-pediatric-deaths-at-cdc-advisory-meeting 2025-09-12T21:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/simris-biologics-secures-eur200k-grant-to-develop-novel-microcystin-based-adc-payloads-for-cancer-therapy 2025-09-12T17:18:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simris-biologics-secures-eur200k-grant-to-develop-novel-microcystin-based-adc-payloads-for-cancer-therapy 2025-09-12T17:18:27+00:00 hourly 0.9 https://trial.medpath.com/news/alx-oncology-appoints-barbara-klencke-as-interim-chief-medical-officer-to-advance-cancer-pipeline 2025-09-12T17:16:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alx-oncology-appoints-barbara-klencke-as-interim-chief-medical-officer-to-advance-cancer-pipeline 2025-09-12T17:16:32+00:00 hourly 0.9 https://trial.medpath.com/news/galimedix-therapeutics-completes-phase-1-trial-of-oral-alzheimer-s-drug-gal-101 2025-09-12T17:16:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galimedix-therapeutics-completes-phase-1-trial-of-oral-alzheimer-s-drug-gal-101 2025-09-12T17:16:29+00:00 hourly 0.9 https://trial.medpath.com/news/gelteq-achieves-first-u-s-commercial-milestone-with-partner-s-nutraceutical-product-launch 2025-09-12T17:11:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gelteq-achieves-first-u-s-commercial-milestone-with-partner-s-nutraceutical-product-launch 2025-09-12T17:11:41+00:00 hourly 0.9 https://trial.medpath.com/news/pulnovo-medical-secures-fda-ide-approvals-for-padn-system-clinical-trials-with-cms-coverage 2025-09-12T17:11:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulnovo-medical-secures-fda-ide-approvals-for-padn-system-clinical-trials-with-cms-coverage 2025-09-12T17:11:36+00:00 hourly 0.9 https://trial.medpath.com/news/maia-biotechnology-s-ateganosine-shows-promising-efficacy-in-phase-ii-nsclc-trial 2025-09-12T17:11:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maia-biotechnology-s-ateganosine-shows-promising-efficacy-in-phase-ii-nsclc-trial 2025-09-12T17:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/china-announces-national-hpv-vaccination-program-as-domestic-nine-valent-vaccine-launches 2025-09-12T13:14:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-announces-national-hpv-vaccination-program-as-domestic-nine-valent-vaccine-launches 2025-09-12T13:14:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-moves-to-eliminate-expert-advisory-panels-for-individual-drug-reviews-under-trump-administration 2025-09-12T13:11:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-moves-to-eliminate-expert-advisory-panels-for-individual-drug-reviews-under-trump-administration 2025-09-12T13:11:29+00:00 hourly 0.9 https://trial.medpath.com/news/united-therapeutics-to-present-phase-3-teton-2-data-for-inhaled-treprostinil-in-idiopathic-pulmonary-fibrosis-at-ers-congress 2025-09-12T13:10:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/united-therapeutics-to-present-phase-3-teton-2-data-for-inhaled-treprostinil-in-idiopathic-pulmonary-fibrosis-at-ers-congress 2025-09-12T13:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/allterum-therapeutics-receives-fda-clearance-for-4a10-antibody-therapy-in-pediatric-leukemia 2025-09-12T13:10:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allterum-therapeutics-receives-fda-clearance-for-4a10-antibody-therapy-in-pediatric-leukemia 2025-09-12T13:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/city-of-hope-advances-novel-aml-therapies-and-unveils-breakthrough-research-at-ash-2025 2025-09-12T13:10:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/city-of-hope-advances-novel-aml-therapies-and-unveils-breakthrough-research-at-ash-2025 2025-09-12T13:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-shows-anlotinib-improves-survival-and-response-rates-in-nsclc-brain-metastases 2025-09-12T13:10:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meta-analysis-shows-anlotinib-improves-survival-and-response-rates-in-nsclc-brain-metastases 2025-09-12T13:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/inflammasome-therapeutics-k8-implant-reduces-geographic-atrophy-lesion-growth-by-53-in-phase-i-trial 2025-09-12T09:10:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inflammasome-therapeutics-k8-implant-reduces-geographic-atrophy-lesion-growth-by-53-in-phase-i-trial 2025-09-12T09:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/sophont-raises-9-22-million-to-develop-multimodal-ai-platform-for-medical-diagnosis-and-drug-discovery 2025-09-12T09:09:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sophont-raises-9-22-million-to-develop-multimodal-ai-platform-for-medical-diagnosis-and-drug-discovery 2025-09-12T09:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/polyrizon-s-intranasal-barrier-technology-shows-promise-against-respiratory-viruses-and-allergens 2025-09-12T07:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polyrizon-s-intranasal-barrier-technology-shows-promise-against-respiratory-viruses-and-allergens 2025-09-12T07:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/achieve-life-sciences-appoints-dr-mark-rubinstein-as-interim-cmo-amid-cytisinicline-fda-review 2025-09-12T05:09:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/achieve-life-sciences-appoints-dr-mark-rubinstein-as-interim-cmo-amid-cytisinicline-fda-review 2025-09-12T05:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/selinexor-triplet-therapy-shows-significant-survival-benefit-in-pi-naive-multiple-myeloma-patients 2025-09-12T05:08:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/selinexor-triplet-therapy-shows-significant-survival-benefit-in-pi-naive-multiple-myeloma-patients 2025-09-12T05:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/world-gu-2025-highlights-advances-in-variant-histology-management-and-community-oncology-care-for-genitourinary-cancers 2025-09-12T02:09:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-gu-2025-highlights-advances-in-variant-histology-management-and-community-oncology-care-for-genitourinary-cancers 2025-09-12T02:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-appoints-former-eli-lilly-executive-rhonda-pacheco-to-lead-u-s-operations 2025-09-12T01:15:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-appoints-former-eli-lilly-executive-rhonda-pacheco-to-lead-u-s-operations 2025-09-12T01:15:01+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-scientists-win-prestigious-lasker-award-for-revolutionary-cystic-fibrosis-treatment 2025-09-12T01:14:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-scientists-win-prestigious-lasker-award-for-revolutionary-cystic-fibrosis-treatment 2025-09-12T01:14:51+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-biologics-secures-1-3-billion-us-manufacturing-deal-amid-trade-policy-uncertainty 2025-09-12T01:12:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-biologics-secures-1-3-billion-us-manufacturing-deal-amid-trade-policy-uncertainty 2025-09-12T01:12:01+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-inaugurates-first-us-manufacturing-facility-in-new-jersey-with-30-million-investment 2025-09-12T01:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-inaugurates-first-us-manufacturing-facility-in-new-jersey-with-30-million-investment 2025-09-12T01:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/ge-healthcare-acquires-icometrix-to-strengthen-brain-mri-analysis-capabilities-for-alzheimer-s-drug-monitoring 2025-09-12T01:09:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ge-healthcare-acquires-icometrix-to-strengthen-brain-mri-analysis-capabilities-for-alzheimer-s-drug-monitoring 2025-09-12T01:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-committee-establishes-framework-for-ai-powered-mental-health-chatbots 2025-09-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisory-committee-establishes-framework-for-ai-powered-mental-health-chatbots 2025-09-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-fully-digital-adhd-diagnostic-tool-validated-in-peer-reviewed-study 2025-09-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-fully-digital-adhd-diagnostic-tool-validated-in-peer-reviewed-study 2025-09-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/odyssey-therapeutics-raises-213m-series-d-to-advance-autoimmune-disease-pipeline-after-shelving-ipo-plans 2025-09-11T22:12:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/odyssey-therapeutics-raises-213m-series-d-to-advance-autoimmune-disease-pipeline-after-shelving-ipo-plans 2025-09-11T22:12:46+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-withdraws-dea-marijuana-rules-clearing-path-for-fda-compliant-cannabis-trials 2025-09-11T21:15:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-withdraws-dea-marijuana-rules-clearing-path-for-fda-compliant-cannabis-trials 2025-09-11T21:15:15+00:00 hourly 0.9 https://trial.medpath.com/news/intercept-pharmaceuticals-withdraws-ocaliva-from-u-s-market-following-fda-safety-directive 2025-09-11T21:14:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intercept-pharmaceuticals-withdraws-ocaliva-from-u-s-market-following-fda-safety-directive 2025-09-11T21:14:15+00:00 hourly 0.9 https://trial.medpath.com/news/gene-solutions-secures-patent-for-novel-mitochondrial-therapy-platform-targeting-neurological-diseases 2025-09-11T21:12:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-solutions-secures-patent-for-novel-mitochondrial-therapy-platform-targeting-neurological-diseases 2025-09-11T21:12:24+00:00 hourly 0.9 https://trial.medpath.com/news/ose-immunotherapeutics-completes-enrollment-in-phase-2-trial-testing-tedopi-cancer-vaccine-combinations-for-nsclc 2025-09-11T21:11:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ose-immunotherapeutics-completes-enrollment-in-phase-2-trial-testing-tedopi-cancer-vaccine-combinations-for-nsclc 2025-09-11T21:11:33+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-scientists-develop-nano-tagging-robot-for-enhanced-cancer-immunotherapy 2025-09-11T21:11:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-scientists-develop-nano-tagging-robot-for-enhanced-cancer-immunotherapy 2025-09-11T21:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-510-k-clearance-to-ai-powered-bone-health-technologies-for-orthopedic-care 2025-09-11T21:10:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-510-k-clearance-to-ai-powered-bone-health-technologies-for-orthopedic-care 2025-09-11T21:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/federal-appeals-court-upholds-medicare-drug-price-negotiations-for-novo-nordisk-insulin-products 2025-09-11T21:10:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-appeals-court-upholds-medicare-drug-price-negotiations-for-novo-nordisk-insulin-products 2025-09-11T21:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-national-drug-price-negotiation-policy-dramatically-improves-access-to-innovative-medicines-while-reducing-costs-by-up-to-78 2025-09-11T21:10:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-national-drug-price-negotiation-policy-dramatically-improves-access-to-innovative-medicines-while-reducing-costs-by-up-to-78 2025-09-11T21:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/amd-partners-with-oracle-and-absci-to-accelerate-ai-driven-drug-discovery-using-advanced-gpu-technology 2025-09-11T21:10:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amd-partners-with-oracle-and-absci-to-accelerate-ai-driven-drug-discovery-using-advanced-gpu-technology 2025-09-11T21:10:06+00:00 hourly 0.9 https://trial.medpath.com/news/large-taiwanese-study-reveals-mixed-safety-profile-for-long-term-atropine-use-in-childhood-myopia-treatment 2025-09-11T21:09:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-taiwanese-study-reveals-mixed-safety-profile-for-long-term-atropine-use-in-childhood-myopia-treatment 2025-09-11T21:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-ai-receives-fda-510-k-clearance-for-enhanced-cardiac-imaging-platform-with-t1-and-t2-mapping-capabilities 2025-09-11T21:09:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-ai-receives-fda-510-k-clearance-for-enhanced-cardiac-imaging-platform-with-t1-and-t2-mapping-capabilities 2025-09-11T21:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/n-power-medicine-and-viecure-partner-to-transform-clinical-trial-access-in-community-oncology 2025-09-11T21:09:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/n-power-medicine-and-viecure-partner-to-transform-clinical-trial-access-in-community-oncology 2025-09-11T21:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-receives-fda-approval-for-generic-sodium-oxybate-breaking-jazz-pharmaceuticals-monopoly-in-narcolepsy-treatment 2025-09-11T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amneal-receives-fda-approval-for-generic-sodium-oxybate-breaking-jazz-pharmaceuticals-monopoly-in-narcolepsy-treatment 2025-09-11T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/acne-drug-isotretinoin-shows-promise-for-treating-male-infertility-in-small-study 2025-09-11T21:08:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acne-drug-isotretinoin-shows-promise-for-treating-male-infertility-in-small-study 2025-09-11T21:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/energous-completes-5-million-financing-round-to-advance-wireless-power-technology 2025-09-11T20:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/energous-completes-5-million-financing-round-to-advance-wireless-power-technology 2025-09-11T20:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/actuate-therapeutics-raises-17-25-million-to-advance-gsk-3b-inhibitor-for-difficult-to-treat-cancers 2025-09-11T20:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actuate-therapeutics-raises-17-25-million-to-advance-gsk-3b-inhibitor-for-difficult-to-treat-cancers 2025-09-11T20:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/teleflex-initiates-dubstent-diabetes-trial-testing-dual-device-strategy-for-diabetic-patients-undergoing-pci 2025-09-11T17:23:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teleflex-initiates-dubstent-diabetes-trial-testing-dual-device-strategy-for-diabetic-patients-undergoing-pci 2025-09-11T17:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/nutriband-raises-5-3-million-through-warrant-exercises-to-advance-aversa-fentanyl-abuse-deterrent-patch-toward-fda-submission 2025-09-11T17:21:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nutriband-raises-5-3-million-through-warrant-exercises-to-advance-aversa-fentanyl-abuse-deterrent-patch-toward-fda-submission 2025-09-11T17:21:40+00:00 hourly 0.9 https://trial.medpath.com/news/fibrobiologics-reports-breakthrough-results-for-single-dose-fibroblast-spheroid-therapy-in-chronic-psoriasis 2025-09-11T17:20:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fibrobiologics-reports-breakthrough-results-for-single-dose-fibroblast-spheroid-therapy-in-chronic-psoriasis 2025-09-11T17:20:47+00:00 hourly 0.9 https://trial.medpath.com/news/maze-therapeutics-mze782-shows-42-fold-increase-in-phenylalanine-excretion-in-phase-1-trial-for-pku-and-ckd 2025-09-11T17:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maze-therapeutics-mze782-shows-42-fold-increase-in-phenylalanine-excretion-in-phase-1-trial-for-pku-and-ckd 2025-09-11T17:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/profusa-partners-with-nvidia-to-develop-ai-powered-continuous-biomarker-monitoring-portal 2025-09-11T17:18:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/profusa-partners-with-nvidia-to-develop-ai-powered-continuous-biomarker-monitoring-portal 2025-09-11T17:18:47+00:00 hourly 0.9 https://trial.medpath.com/news/medicines-discovery-catapult-and-crown-bioscience-form-strategic-alliance-to-accelerate-radiopharmaceutical-development 2025-09-11T17:17:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicines-discovery-catapult-and-crown-bioscience-form-strategic-alliance-to-accelerate-radiopharmaceutical-development 2025-09-11T17:17:51+00:00 hourly 0.9 https://trial.medpath.com/news/intercept-pharmaceuticals-voluntarily-withdraws-ocaliva-from-us-market-following-fda-request 2025-09-11T17:17:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intercept-pharmaceuticals-voluntarily-withdraws-ocaliva-from-us-market-following-fda-request 2025-09-11T17:17:16+00:00 hourly 0.9 https://trial.medpath.com/news/roivant-sciences-gains-orphan-drug-designation-in-japan-for-mosliciguat-in-pulmonary-hypertension 2025-09-11T17:15:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roivant-sciences-gains-orphan-drug-designation-in-japan-for-mosliciguat-in-pulmonary-hypertension 2025-09-11T17:15:26+00:00 hourly 0.9 https://trial.medpath.com/news/charles-river-laboratories-forms-strategic-oncology-alliances-to-accelerate-cancer-immunotherapy-development 2025-09-11T17:14:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/charles-river-laboratories-forms-strategic-oncology-alliances-to-accelerate-cancer-immunotherapy-development 2025-09-11T17:14:41+00:00 hourly 0.9 https://trial.medpath.com/news/former-fda-hematologic-malignancies-leader-nicholas-richardson-joins-precision-for-medicine-as-vp-clinical-development 2025-09-11T17:12:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-fda-hematologic-malignancies-leader-nicholas-richardson-joins-precision-for-medicine-as-vp-clinical-development 2025-09-11T17:12:55+00:00 hourly 0.9 https://trial.medpath.com/news/absci-partners-with-oracle-and-amd-to-accelerate-ai-driven-drug-discovery-platform 2025-09-11T17:12:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/absci-partners-with-oracle-and-amd-to-accelerate-ai-driven-drug-discovery-platform 2025-09-11T17:12:16+00:00 hourly 0.9 https://trial.medpath.com/news/nanonewron-secures-2-5m-nih-grant-to-advance-blood-brain-barrier-crossing-tnf-alpha-inhibitor-for-alzheimer-s-disease 2025-09-11T13:16:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanonewron-secures-2-5m-nih-grant-to-advance-blood-brain-barrier-crossing-tnf-alpha-inhibitor-for-alzheimer-s-disease 2025-09-11T13:16:31+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-files-patent-lawsuit-against-ionis-over-plozasiran-fcs-treatment 2025-09-11T13:15:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-files-patent-lawsuit-against-ionis-over-plozasiran-fcs-treatment 2025-09-11T13:15:31+00:00 hourly 0.9 https://trial.medpath.com/news/bausch-lomb-s-envista-envy-iol-demonstrates-superior-visual-performance-in-pivotal-clinical-trial 2025-09-11T13:12:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bausch-lomb-s-envista-envy-iol-demonstrates-superior-visual-performance-in-pivotal-clinical-trial 2025-09-11T13:12:13+00:00 hourly 0.9 https://trial.medpath.com/news/merck-s-capvaxive-shows-superior-immune-response-in-high-risk-children-and-adolescents 2025-09-11T13:11:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-s-capvaxive-shows-superior-immune-response-in-high-risk-children-and-adolescents 2025-09-11T13:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/radiomedix-and-vect-horus-initiate-first-in-human-trial-of-blood-brain-barrier-crossing-radiotracer-for-glioblastoma-and-pancreatic-cancer 2025-09-11T13:11:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiomedix-and-vect-horus-initiate-first-in-human-trial-of-blood-brain-barrier-crossing-radiotracer-for-glioblastoma-and-pancreatic-cancer 2025-09-11T13:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-restructures-global-operations-exits-27-markets-through-strategic-partnership-model 2025-09-11T13:10:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-restructures-global-operations-exits-27-markets-through-strategic-partnership-model 2025-09-11T13:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/apple-watch-receives-fda-approval-for-hypertension-detection-feature-expected-to-identify-over-one-million-undiagnosed-cases 2025-09-11T13:09:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apple-watch-receives-fda-approval-for-hypertension-detection-feature-expected-to-identify-over-one-million-undiagnosed-cases 2025-09-11T13:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/musc-hollings-cancer-center-launches-automain-trial-testing-repurposed-drugs-for-recurrent-ovarian-cancer 2025-09-11T11:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/musc-hollings-cancer-center-launches-automain-trial-testing-repurposed-drugs-for-recurrent-ovarian-cancer 2025-09-11T11:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/minnesota-develops-innovative-learning-health-care-community-model-to-bridge-research-practice-gap 2025-09-11T10:10:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minnesota-develops-innovative-learning-health-care-community-model-to-bridge-research-practice-gap 2025-09-11T10:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-laboratories-acquires-johnson-johnson-s-stugeron-brand-for-50-5-million-to-expand-cns-portfolio 2025-09-11T09:09:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-reddy-s-laboratories-acquires-johnson-johnson-s-stugeron-brand-for-50-5-million-to-expand-cns-portfolio 2025-09-11T09:09:39+00:00 hourly 0.9 https://trial.medpath.com/news/tg-therapeutics-to-present-six-year-briumvi-data-at-ectrims-2025-showcasing-long-term-multiple-sclerosis-treatment-outcomes 2025-09-11T09:09:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tg-therapeutics-to-present-six-year-briumvi-data-at-ectrims-2025-showcasing-long-term-multiple-sclerosis-treatment-outcomes 2025-09-11T09:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/camp4-therapeutics-secures-100-million-financing-to-advance-first-in-class-syngap1-treatment 2025-09-11T09:09:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/camp4-therapeutics-secures-100-million-financing-to-advance-first-in-class-syngap1-treatment 2025-09-11T09:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-advances-two-breakthrough-rnai-therapeutics-into-clinical-trials 2025-09-11T09:09:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-advances-two-breakthrough-rnai-therapeutics-into-clinical-trials 2025-09-11T09:09:08+00:00 hourly 0.9 https://trial.medpath.com/news/tagworks-pharmaceuticals-advances-tgw101-to-third-dose-level-in-phase-1-trial-for-solid-tumors 2025-09-11T09:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tagworks-pharmaceuticals-advances-tgw101-to-third-dose-level-in-phase-1-trial-for-solid-tumors 2025-09-11T09:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/bioxodes-reports-promising-phase-2a-results-for-biox-101-in-intracerebral-hemorrhage-treatment 2025-09-11T09:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioxodes-reports-promising-phase-2a-results-for-biox-101-in-intracerebral-hemorrhage-treatment 2025-09-11T09:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/teva-and-medincell-s-long-acting-risperidone-injection-expands-global-reach-with-canadian-approval 2025-09-11T09:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-and-medincell-s-long-acting-risperidone-injection-expands-global-reach-with-canadian-approval 2025-09-11T09:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-health-ventures-makes-inaugural-investment-in-delix-therapeutics-non-hallucinogenic-depression-treatment 2025-09-11T09:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-davis-health-ventures-makes-inaugural-investment-in-delix-therapeutics-non-hallucinogenic-depression-treatment 2025-09-11T09:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/targeted-antioxidants-reverse-t-cell-exhaustion-by-protecting-telomeres-in-cancer-therapy 2025-09-11T05:09:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/targeted-antioxidants-reverse-t-cell-exhaustion-by-protecting-telomeres-in-cancer-therapy 2025-09-11T05:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/xingimaging-and-synusight-receive-3-84m-grant-to-advance-first-a-synuclein-pet-tracer-for-parkinson-s-disease 2025-09-11T05:09:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xingimaging-and-synusight-receive-3-84m-grant-to-advance-first-a-synuclein-pet-tracer-for-parkinson-s-disease 2025-09-11T05:09:47+00:00 hourly 0.9 https://trial.medpath.com/news/capsida-suspends-gene-therapy-trial-after-first-patient-dies-following-treatment-for-rare-stxbp1-disorder 2025-09-11T05:09:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capsida-suspends-gene-therapy-trial-after-first-patient-dies-following-treatment-for-rare-stxbp1-disorder 2025-09-11T05:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-imdelltra-receives-fda-approval-and-guideline-upgrade-rocatinlimab-phase-3-data-awaited 2025-09-11T05:09:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-s-imdelltra-receives-fda-approval-and-guideline-upgrade-rocatinlimab-phase-3-data-awaited 2025-09-11T05:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/precision-tools-transform-breast-cancer-survivorship-care-as-patients-navigate-post-treatment-challenges 2025-09-11T05:09:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-tools-transform-breast-cancer-survivorship-care-as-patients-navigate-post-treatment-challenges 2025-09-11T05:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/dewpoint-therapeutics-secures-series-d-funding-to-advance-novel-condensate-modulator-for-gastric-cancer 2025-09-11T01:10:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dewpoint-therapeutics-secures-series-d-funding-to-advance-novel-condensate-modulator-for-gastric-cancer 2025-09-11T01:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-major-crackdown-on-misleading-pharmaceutical-advertising-under-trump-administration 2025-09-11T01:10:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-launches-major-crackdown-on-misleading-pharmaceutical-advertising-under-trump-administration 2025-09-11T01:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/nih-study-shows-jail-based-opioid-treatment-reduces-fatal-overdoses-by-52-and-improves-post-release-outcomes 2025-09-11T01:10:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-study-shows-jail-based-opioid-treatment-reduces-fatal-overdoses-by-52-and-improves-post-release-outcomes 2025-09-11T01:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/sagimet-s-denifanstat-shows-significant-anti-fibrotic-benefits-in-advanced-mash-patients-at-aasld-2025 2025-09-11T01:09:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sagimet-s-denifanstat-shows-significant-anti-fibrotic-benefits-in-advanced-mash-patients-at-aasld-2025 2025-09-11T01:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/neurosense-s-primec-shows-enhanced-neuroplasticity-in-alzheimer-s-patient-derived-neurons 2025-09-11T01:09:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurosense-s-primec-shows-enhanced-neuroplasticity-in-alzheimer-s-patient-derived-neurons 2025-09-11T01:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-maine-researchers-develop-sustainable-wood-based-production-method-for-key-pharmaceutical-building-block 2025-09-11T01:09:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-maine-researchers-develop-sustainable-wood-based-production-method-for-key-pharmaceutical-building-block 2025-09-11T01:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/design-therapeutics-appoints-former-gw-pharmaceuticals-ceo-justin-gover-to-board-of-directors 2025-09-11T01:09:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/design-therapeutics-appoints-former-gw-pharmaceuticals-ceo-justin-gover-to-board-of-directors 2025-09-11T01:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/bassett-research-institute-receives-12-million-pcori-grant-to-study-kidney-effects-of-common-antibiotic-combination 2025-09-11T01:07:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bassett-research-institute-receives-12-million-pcori-grant-to-study-kidney-effects-of-common-antibiotic-combination 2025-09-11T01:07:59+00:00 hourly 0.9 https://trial.medpath.com/news/apozeal-pharmaceuticals-secures-4-1m-investment-to-expand-generic-drug-manufacturing-in-pennsylvania 2025-09-11T01:07:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apozeal-pharmaceuticals-secures-4-1m-investment-to-expand-generic-drug-manufacturing-in-pennsylvania 2025-09-11T01:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/centinel-spine-achieves-fda-approval-for-two-level-cervical-disc-replacement-with-record-breaking-clinical-success-rate 2025-09-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/centinel-spine-achieves-fda-approval-for-two-level-cervical-disc-replacement-with-record-breaking-clinical-success-rate 2025-09-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fibrobiologics-reports-breakthrough-in-bone-marrow-organoid-platform-for-cancer-and-immune-system-regeneration 2025-09-10T21:16:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fibrobiologics-reports-breakthrough-in-bone-marrow-organoid-platform-for-cancer-and-immune-system-regeneration 2025-09-10T21:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/lutetium-lu-177-dotatate-shows-promise-in-metastatic-bronchopulmonary-neuroendocrine-tumors 2025-09-10T21:16:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lutetium-lu-177-dotatate-shows-promise-in-metastatic-bronchopulmonary-neuroendocrine-tumors 2025-09-10T21:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/basal-cell-neoplasm-drug-pipeline-expands-with-22-companies-developing-novel-therapies 2025-09-10T21:15:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/basal-cell-neoplasm-drug-pipeline-expands-with-22-companies-developing-novel-therapies 2025-09-10T21:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/jak1-inhibitors-show-superior-antipruritic-effects-over-il-13-antibodies-in-atopic-dermatitis 2025-09-10T21:15:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jak1-inhibitors-show-superior-antipruritic-effects-over-il-13-antibodies-in-atopic-dermatitis 2025-09-10T21:15:24+00:00 hourly 0.9 https://trial.medpath.com/news/nurexone-s-exopten-shows-promising-results-in-spinal-cord-injury-and-glaucoma-preclinical-studies 2025-09-10T21:13:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nurexone-s-exopten-shows-promising-results-in-spinal-cord-injury-and-glaucoma-preclinical-studies 2025-09-10T21:13:47+00:00 hourly 0.9 https://trial.medpath.com/news/merck-abandons-ps1-billion-london-research-centre-cuts-125-uk-science-jobs 2025-09-10T21:13:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-abandons-ps1-billion-london-research-centre-cuts-125-uk-science-jobs 2025-09-10T21:13:31+00:00 hourly 0.9 https://trial.medpath.com/news/france-approves-compassionate-access-for-agenus-bot-bal-immunotherapy-in-refractory-mss-colorectal-cancer 2025-09-10T21:13:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/france-approves-compassionate-access-for-agenus-bot-bal-immunotherapy-in-refractory-mss-colorectal-cancer 2025-09-10T21:13:23+00:00 hourly 0.9 https://trial.medpath.com/news/kfshrc-achieves-first-locally-manufactured-car-t-cell-treatment-in-saudi-arabia 2025-09-10T21:12:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kfshrc-achieves-first-locally-manufactured-car-t-cell-treatment-in-saudi-arabia 2025-09-10T21:12:55+00:00 hourly 0.9 https://trial.medpath.com/news/new-retinal-formulation-retaxome-shows-enhanced-tolerability-in-clinical-studies 2025-09-10T21:11:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-retinal-formulation-retaxome-shows-enhanced-tolerability-in-clinical-studies 2025-09-10T21:11:07+00:00 hourly 0.9 https://trial.medpath.com/news/merck-halts-u-k-research-operations-abandons-london-facility-over-nhs-drug-pricing-disputes 2025-09-10T21:10:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-halts-u-k-research-operations-abandons-london-facility-over-nhs-drug-pricing-disputes 2025-09-10T21:10:30+00:00 hourly 0.9 https://trial.medpath.com/news/truleaf-achieves-first-in-human-implantation-of-revolutionary-catheter-based-heart-valve-system 2025-09-10T21:10:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/truleaf-achieves-first-in-human-implantation-of-revolutionary-catheter-based-heart-valve-system 2025-09-10T21:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/500000-grant-expands-phase-2-trial-of-wokvac-breast-cancer-vaccine-at-university-of-washington 2025-09-10T21:10:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/500000-grant-expands-phase-2-trial-of-wokvac-breast-cancer-vaccine-at-university-of-washington 2025-09-10T21:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/dianthus-therapeutics-soars-50-following-positive-phase-2-results-for-myasthenia-gravis-drug 2025-09-10T17:32:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dianthus-therapeutics-soars-50-following-positive-phase-2-results-for-myasthenia-gravis-drug 2025-09-10T17:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/innorna-completes-phase-ii-enrollment-for-world-s-first-bivalent-rsv-mrna-vaccine 2025-09-10T17:29:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innorna-completes-phase-ii-enrollment-for-world-s-first-bivalent-rsv-mrna-vaccine 2025-09-10T17:29:50+00:00 hourly 0.9 https://trial.medpath.com/news/imaging-endpoints-files-patent-for-ai-enhanced-imaging-review-charter-system-to-optimize-oncology-trials 2025-09-10T17:29:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imaging-endpoints-files-patent-for-ai-enhanced-imaging-review-charter-system-to-optimize-oncology-trials 2025-09-10T17:29:43+00:00 hourly 0.9 https://trial.medpath.com/news/ppar-gamma-pathway-modulation-enhances-nectin4-targeted-car-t-therapy-for-bladder-cancer 2025-09-10T17:29:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ppar-gamma-pathway-modulation-enhances-nectin4-targeted-car-t-therapy-for-bladder-cancer 2025-09-10T17:29:16+00:00 hourly 0.9 https://trial.medpath.com/news/exact-sciences-launches-cancerguard-multi-cancer-blood-test-for-early-detection 2025-09-10T17:27:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exact-sciences-launches-cancerguard-multi-cancer-blood-test-for-early-detection 2025-09-10T17:27:22+00:00 hourly 0.9 https://trial.medpath.com/news/sublingual-edaravone-dexborneol-tablet-shows-superior-cost-effectiveness-for-acute-ischemic-stroke-treatment 2025-09-10T17:26:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sublingual-edaravone-dexborneol-tablet-shows-superior-cost-effectiveness-for-acute-ischemic-stroke-treatment 2025-09-10T17:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/kadimastem-and-nls-pharmaceutics-clear-final-sec-hurdle-for-merger-creating-newcelx 2025-09-10T17:25:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kadimastem-and-nls-pharmaceutics-clear-final-sec-hurdle-for-merger-creating-newcelx 2025-09-10T17:25:59+00:00 hourly 0.9 https://trial.medpath.com/news/galectin-therapeutics-belapectin-shows-49-reduction-in-liver-varices-stock-hits-52-week-high 2025-09-10T17:25:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galectin-therapeutics-belapectin-shows-49-reduction-in-liver-varices-stock-hits-52-week-high 2025-09-10T17:25:54+00:00 hourly 0.9 https://trial.medpath.com/news/cuspai-raises-100-million-series-a-to-accelerate-ai-driven-materials-discovery-for-healthcare-and-sustainability 2025-09-10T17:24:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cuspai-raises-100-million-series-a-to-accelerate-ai-driven-materials-discovery-for-healthcare-and-sustainability 2025-09-10T17:24:48+00:00 hourly 0.9 https://trial.medpath.com/news/tepotinib-shows-high-frequency-of-adverse-events-but-manageable-safety-profile-in-met-exon-14-altered-nsclc 2025-09-10T17:24:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tepotinib-shows-high-frequency-of-adverse-events-but-manageable-safety-profile-in-met-exon-14-altered-nsclc 2025-09-10T17:24:40+00:00 hourly 0.9 https://trial.medpath.com/news/symeres-acquires-dgr-pharma-to-strengthen-integrated-drug-development-services 2025-09-10T17:22:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/symeres-acquires-dgr-pharma-to-strengthen-integrated-drug-development-services 2025-09-10T17:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/euda-health-signs-letter-of-intent-to-acquire-ipsc-platform-developer-go-posb-for-regenerative-medicine-expansion 2025-09-10T17:21:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/euda-health-signs-letter-of-intent-to-acquire-ipsc-platform-developer-go-posb-for-regenerative-medicine-expansion 2025-09-10T17:21:38+00:00 hourly 0.9 https://trial.medpath.com/news/mednovo-doses-first-patient-in-phase-iii-trial-of-lutetium-177-radiotherapy-for-neuroendocrine-tumors 2025-09-10T17:21:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mednovo-doses-first-patient-in-phase-iii-trial-of-lutetium-177-radiotherapy-for-neuroendocrine-tumors 2025-09-10T17:21:35+00:00 hourly 0.9 https://trial.medpath.com/news/aurora-2-study-shows-no-increased-nephrotoxicity-with-voclosporin-in-lupus-nephritis-after-18-months 2025-09-10T17:21:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurora-2-study-shows-no-increased-nephrotoxicity-with-voclosporin-in-lupus-nephritis-after-18-months 2025-09-10T17:21:29+00:00 hourly 0.9 https://trial.medpath.com/news/greenwich-lifesciences-glsi-100-receives-fda-fast-track-designation-for-her2-positive-breast-cancer 2025-09-10T17:19:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greenwich-lifesciences-glsi-100-receives-fda-fast-track-designation-for-her2-positive-breast-cancer 2025-09-10T17:19:54+00:00 hourly 0.9 https://trial.medpath.com/news/dermata-therapeutics-pivots-from-prescription-to-otc-dermatology-products-following-successful-phase-3-acne-trial 2025-09-10T17:19:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dermata-therapeutics-pivots-from-prescription-to-otc-dermatology-products-following-successful-phase-3-acne-trial 2025-09-10T17:19:22+00:00 hourly 0.9 https://trial.medpath.com/news/pmv-pharma-s-rezatapopt-demonstrates-33-response-rate-in-phase-2-trial-for-tp53-y220c-solid-tumors 2025-09-10T17:19:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pmv-pharma-s-rezatapopt-demonstrates-33-response-rate-in-phase-2-trial-for-tp53-y220c-solid-tumors 2025-09-10T17:19:19+00:00 hourly 0.9 https://trial.medpath.com/news/orimed-pharma-launches-prsolufy-first-liquid-aripiprazole-solution-in-canada 2025-09-10T17:19:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orimed-pharma-launches-prsolufy-first-liquid-aripiprazole-solution-in-canada 2025-09-10T17:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/iqvia-launches-ai-powered-clinical-trial-financial-suite-to-automate-site-payments-and-budget-management 2025-09-10T17:18:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iqvia-launches-ai-powered-clinical-trial-financial-suite-to-automate-site-payments-and-budget-management 2025-09-10T17:18:18+00:00 hourly 0.9 https://trial.medpath.com/news/greenwich-lifesciences-glsi-100-receives-fda-fast-track-designation-for-her2-positive-breast-cancer-prevention 2025-09-10T13:15:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greenwich-lifesciences-glsi-100-receives-fda-fast-track-designation-for-her2-positive-breast-cancer-prevention 2025-09-10T13:15:04+00:00 hourly 0.9 https://trial.medpath.com/news/celcuity-secures-500-million-credit-facility-following-positive-phase-3-data-for-gedatolisib-in-advanced-breast-cancer 2025-09-10T13:12:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celcuity-secures-500-million-credit-facility-following-positive-phase-3-data-for-gedatolisib-in-advanced-breast-cancer 2025-09-10T13:12:13+00:00 hourly 0.9 https://trial.medpath.com/news/aphaia-pharma-advances-oral-glucose-based-obesity-treatment-with-second-phase-2-trial 2025-09-10T13:10:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aphaia-pharma-advances-oral-glucose-based-obesity-treatment-with-second-phase-2-trial 2025-09-10T13:10:33+00:00 hourly 0.9 https://trial.medpath.com/news/cascade-bio-raises-6m-to-advance-cell-free-biocatalyst-technology-for-industrial-manufacturing 2025-09-10T13:10:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cascade-bio-raises-6m-to-advance-cell-free-biocatalyst-technology-for-industrial-manufacturing 2025-09-10T13:10:30+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-obagi-saypha-magiq-injectable-hyaluronic-acid-filler-marking-waldencast-s-entry-into-us-dermal-filler-market 2025-09-10T13:10:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-obagi-saypha-magiq-injectable-hyaluronic-acid-filler-marking-waldencast-s-entry-into-us-dermal-filler-market 2025-09-10T13:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/diamyd-medical-secures-key-patents-for-precision-medicine-approach-to-type-1-diabetes-treatment 2025-09-10T13:09:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diamyd-medical-secures-key-patents-for-precision-medicine-approach-to-type-1-diabetes-treatment 2025-09-10T13:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/revelation-biosciences-gemini-shows-promise-in-phase-1b-trial-for-chronic-kidney-disease 2025-09-10T13:09:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revelation-biosciences-gemini-shows-promise-in-phase-1b-trial-for-chronic-kidney-disease 2025-09-10T13:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/cutiss-raises-eur57-9m-series-c-to-advance-phase-3-trial-of-personalized-skin-graft-therapy 2025-09-10T13:09:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cutiss-raises-eur57-9m-series-c-to-advance-phase-3-trial-of-personalized-skin-graft-therapy 2025-09-10T13:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/triple-negative-breast-cancer-pipeline-expands-with-170-emerging-therapies-as-companies-advance-novel-treatment-approaches 2025-09-10T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triple-negative-breast-cancer-pipeline-expands-with-170-emerging-therapies-as-companies-advance-novel-treatment-approaches 2025-09-10T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/vedabio-secures-40m-series-a-and-strategic-partnership-with-siemens-healthineers-for-crispr-diagnostics-platform 2025-09-10T09:17:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vedabio-secures-40m-series-a-and-strategic-partnership-with-siemens-healthineers-for-crispr-diagnostics-platform 2025-09-10T09:17:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-sobi-s-nasp-biologics-license-application-for-uncontrolled-gout-treatment 2025-09-10T09:17:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-sobi-s-nasp-biologics-license-application-for-uncontrolled-gout-treatment 2025-09-10T09:17:07+00:00 hourly 0.9 https://trial.medpath.com/news/resolution-therapeutics-strengthens-leadership-team-with-key-executive-appointments-as-rtx001-advances-in-clinical-trials 2025-09-10T08:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/resolution-therapeutics-strengthens-leadership-team-with-key-executive-appointments-as-rtx001-advances-in-clinical-trials 2025-09-10T08:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/iga-nephropathy-pipeline-shows-strong-growth-with-30-therapies-in-development-across-multiple-clinical-stages 2025-09-10T07:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iga-nephropathy-pipeline-shows-strong-growth-with-30-therapies-in-development-across-multiple-clinical-stages 2025-09-10T07:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-bylvay-for-alagille-syndrome-treatment-marking-first-dual-indication-rare-disease-therapy 2025-09-10T06:09:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-bylvay-for-alagille-syndrome-treatment-marking-first-dual-indication-rare-disease-therapy 2025-09-10T06:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/beckman-coulter-life-sciences-partners-with-hse-ag-to-automate-nucleic-acid-quantification-workflows 2025-09-10T06:08:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beckman-coulter-life-sciences-partners-with-hse-ag-to-automate-nucleic-acid-quantification-workflows 2025-09-10T06:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/varian-secures-first-european-approval-for-knee-arthritis-embolization-device 2025-09-10T06:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/varian-secures-first-european-approval-for-knee-arthritis-embolization-device 2025-09-10T06:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/scenic-biotech-appoints-dr-roland-w-burli-as-chief-scientific-officer-to-advance-modifier-therapy-pipeline 2025-09-10T06:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scenic-biotech-appoints-dr-roland-w-burli-as-chief-scientific-officer-to-advance-modifier-therapy-pipeline 2025-09-10T06:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-koala-chlamydia-vaccine-receives-regulatory-approval-in-australia 2025-09-10T04:08:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-s-first-koala-chlamydia-vaccine-receives-regulatory-approval-in-australia 2025-09-10T04:08:59+00:00 hourly 0.9 https://trial.medpath.com/news/qiagen-receives-fda-clearance-for-qiastat-dx-rise-system-launches-globally-across-100-countries 2025-09-10T01:19:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qiagen-receives-fda-clearance-for-qiastat-dx-rise-system-launches-globally-across-100-countries 2025-09-10T01:19:52+00:00 hourly 0.9